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Mast cells play pivotal roles in immunoglobulin (Ig) E-mediated airway 
inflammation and other mast cell-mediated inflammation by interacting and recruiting 
inflammatory cells after activated by cytokines in the inflamed tissues. 
In the present study, we first investigated the intracellular signaling mechanisms 
regulating the induction of chemokines and adhesion molecules from human mast cell 
line-1 (HMC-1) under the effects of different cytokines. Based on the findings, we 
then assessed the in vitro anti-allergic activities of a Wheeze-relief formula composed 
of 5 herbs of traditional Chinese medicine (TCM) on HMC-1 cells. 
To generate a profile of chemokine and adhesion molecule expression under the 
effects of cytokines, we assayed the expression of interieukin (IL)-8, monocyte 
chemoattractant protein (MCP)-l, regulated upon activation normal T-cell expressed 
and secreted (RANTES), 1-309, macrophage inflammatory protein (MIP)-lp, 
interferon-y-inducible protein-10 (IP-10), intercellular adhesion molecule (ICAM)-l 
and ICAM-3 of the HMC-1 cells after treating with stem cell factor (SCF), tumor 
necrosis factor (TNF)-a, IL-13, IL-18 and IL-25. IL-8, MCP-1, RANTES and IP-10 
were quantitated by flow cytometry based cytometric beads array (CBA). ELISA was 
used to measure the release of 1-309 and MIP-ip. Cell surface expressed ICAM-1 and 
ICAM-3 were assayed by flow cytometry. Gene expression levels were also studied 
using reverse transcription-polymerase chain reaction (RT-PCR). 
Results showed that SCF and TNF-a could induce the release of IL-8, MCP-1, 
RANTES and 1-309. MIP-lp and IP-10 were upregulated by SCF and TNF-a 
respectively. IL-13, IL-18 and IL-25 had no effect on all the chemokines. Expression 
of ICAM-1 could be induced by SCF, TNF-a and IL-13 but not IL-18 and IL-25. It 
was also shown that combined treatment of (SCF + IL-13) and (SCF + TNF-a) had an 
vi 
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additive and synergistic effect on the ICAM-1 expression respectively. All cytokines 
had no effect on the expression of ICAM-3. 
Since SCF and TNF-a showed most potent effects on IL-8, MCP-1, RANTES, 
1-309, MIP-ip, IP-10 and ICAM-1, we then focused on their effects in activating 
intracellular signal transduction pathways of extracellular signal-regulated kinase 
(ERK), p38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-KB. 
Activation of these pathways was quantitatively assessed by ELISA. Selective 
inhibitors of the pathways including PD98059 for ERK pathway, SB203580 for p38 
MAPK pathway and BAY 117082 for NF-KB pathway, were also used to confirm the 
regulatory mechanisms for the effects of SCF and TNF-a. 
We found that the SCF-induced upregulation of IL-8, MCP-1, RANTES, 1-309. 
MIP-ip and ICAM-1 were mediated through ERK pathway. The TNF-a-induced 
upregulation of IL-8, MCP-1,1-309 and IP-10 were mediated by p38 MAPK pathway. 
Besides, NF-KB pathway was responsible to conduct the TNF-a-induced IP-10, 
RANTES and ICAM-1. The results also suggested that SCF-induced activation of 
ERK could enhance the TNF-a-induced activation of NF-KB pathway, thereby giving 
the synergistic upregulation of ICAM-1 expression. 
To investigate the in vitro anti-allergic activities of the Wheeze-relief formula, we 
studied the effects of the five herbal components, including Cordyceps sinensis (冬蟲 
夏草)，Bulhus Fritillariae cirrhosae (川貝)，Radix Stemonae (百音R), Radix astragali 
(黃耆）and Radix Scutellariae (黃夸）on the SCF-induced release of 1-309 and MCP-1 
from the HMC-1. It was because 1-309 and MCP-1 can specifically attract the T 
helper (Th)2-cells for bringing out allergic responses. However, the five herbs could 
not show a specific downregulation on the release of these 2 chemokines. 
In conclusion, we have elucidated the different intracellular signaling pathways 
馕 
regulating the chemokine and adhesion molecule expression of SCF and TNF-a 
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activated mast cells. It provides important information for generating biological and 
pharmacological implications on treating mast cell-mediated diseases. Besides, we 
have also shown that these studies may help to develop parameters to investigate the 
therapeutic mechanisms of TCM. 
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況’我們檢測了經幹细胞因子（stem cell factor, SCF),腫瘤壞死因子（tumor 
necrosis factor,TNF)-a, IL-13, IL-18 禾n IL-25 剌激後，白介素（interleukin, IL)-8, 
單核细胞趨化蛋白（monocyte chemoattractant protein, MCP)-1,激活時可調節的 
正常 T 细月包表達禾口分泌、因子(regulated upon activation normal T-cell expressed and 
secreted , RANTES), 1-309,巨噬细胞炎症蛋白（macrophage inflammatory 
protein , MIP)-ip, Y干擾素誘生蛋白（interferon-丫-inducible protein, IP)-10,細胞間 
S占附分子(intercellular adhesion molecule, ICAM)-1 禾口 ICAM-3 的表達。IL-8, 
MCP-1, RANTES 禾CI IP-10 用流式蛋白分析系統（cytometric beads array, CBA)來 
定量。用酶聯免疫法（ELISA)測定1-309和MIP-1(3。細胞表面ICAM-1和 
ICAM-3用流式細胞儀檢測。而基因表達則用逆轉錄-聚合酶鏈反應（reverse 
transcription- polymerase-chain-reaction, RT-PCR)分析。 
結果顯示，SCF和TNF-a可以誘導HMCM細胞釋放IL-8, MCP-1, RANTES 





由於 SCF 禾口 TNF-a 對 IL-8, MCP-1, RANTES, 1-309, MIP-ip, IP-10 禾口 
ICAM-1在HMC-1細胞表達都有顯著誘導作用，所以我們重點硏究了它們對細 
胞内信號傳導通路中的细胞外信號調節激酶(extracellular signal-regulated kinase, 
ix 
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ERK) ’ p38 絲裂原活化蛋白激酶（mitogen-activated protein kinase, MAPK)和核 
因子(nudear factor, NF)-KB的影響。這些酶活性用酶聯免疫法所分析。運用信號 
傳導道路中酶的選擇性抑制劑：抑制E R K的P D 9 8 0 5 9，抑制P 3 8 M A P K的 
S B 2 0 3 5 8 0和抑制N F - K B的B A Y 1 1 7 0 8 2，進一步確認 S C F和T N F - A活化 
HMC-1細胞的信號傳導途徑。 
硏究結果發現，經 SCF 誘導的 IL-8, MCP-1，RANTES, 1-309, MIP-ip 和 
ICAM-1表達是經由ERK途徑。TNF-a誘導的IL-8, MCP-1,1-309和IP-10的釋 
放是通過p3 8 MAPK途徑。而TNF-a誘導的IP-10, RANTES和 ICAM-1的表達 
則是通過N F -KB途徑。結果還顯示經S C F誘導的E R K活性可提升T N F - A誘導 
的NF-KB路徑的活性，並對ICAM-1表達具有協同作用。 
爲了探討中藥平喘單方體外抗敏活性，我們硏究了五種中藥：冬蟲夏草 
{Cordyceps sinensis),川貝{Bulbus Fritillariae cirrhosae),百咅{Radix Stemonae ), 
黃耆 [ R a d i x astragali) and 黃夸{Rad ix Scutellariae)對 SCF 活化的 HMC-1 細胞 
釋放1-309和MCP-1的影響。因爲1-309和MCP-1可以選擇性吸弓| I I型輔助型 
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Chapter I Introduction 
Chapter 1 
Introduction 
1.1 Human mast cells and their pathological roles in inflammation 
1.1.1 Morphology of mast cells 
Mast cells are leukocytes ranging from 5 to 30 jim in diameter. The shape of the mast cells 
vary dependent on tissue location and has been described as polyhedral, fusiform, ovoid, and 
rectangular with a round or oval nuclei [He et al, 2004]. The most characteristic feature of 
mast cells is their cytoplasmic granules which vary in size from 0.2 to 0.5 jim in diameter 
that can occupy up to 40% of the volumn of mast cells [Bischoff et al, 2002]. 
1.1.2 Mediators of mast cells 
Numerous mediators are stored in metachromatic granules and can be released at the time 
of stimulation to bring out the biological functions. The mediators are generally divided into 
three subclasses: (1) preformed mediators including histamine, tryptase, chymase and 
proteoglycans; (2) newly generated mediators including eicosanoids, leukotrienes, 
prostaglandins and platelet activating factor [Kawakami et al, 2002]; and (3) an array of 
cytokines and chemokines, including interleukin (IL)-4, IL-5, IL-6, tumor necrosis factor 
(TNF)-a, IL-1(3, IL-8, IL-13, IL-18, IL-25, granulocyte-macrophage colony-stimulating 
factor (GM-CSF), stem cell factor (SCF), macrophage chemotactic peptide (MCP)-l, 2, 3, 
regulated on activation of normal T cell-expressed and secreted protein (RANTES) and 
eotaxin [He et al, 2004]. 
1 
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Figure 1.1 Basic structures of human mast cell and its mediators 
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1.1.3 Migration and activation 
Mast cells arise from multipotent CD34+ precursors in the bone marrow and circulate in 
the peripheral blood as non-granular, monocytic appearing cells. After migrating into tissues, 
these immature mast cells assume their typical granular morphology and become CD34-/ 
c-kit+/ FC8R11(1OW affinity IgE receptor)- and FcsRl(high affinity IgE receptor)+ [Rottem et 
al, 1994]. 
The best characterized stimulus of mast cells is bridging of FceRl receptors by specific 
divalent antigens. This event leads to fusion of mast cells secretory granule membrane with 
the plasma membrane and subsequent release of granule contents. Mast cell activation can 
also occur through exogenous agents, such as antigens and opiates; and endogenous 
molecules, such as cytokines and autoantibodies [He et al, 2004]. 
1.1.4 Pathological roles of mast cells 
Mast cells are historically known to be the central effector cells in type 1 hypersensitivity 
such as allergic bronchial asthma, atopic rhinitis and urticaria [Pawankar et al, 2003]. It is 
because mast cells have been well demonstrated for their IgE-mediated release of mediators 
in the immediate phase reaction of allergic diseases [Oliveira et al, 2001]. The mediators 
released upon allergen stimulation can lead to the symptoms of allergy by increasing 
vasopermeability, contracting smooth muscle and increasing mucus production. Mast cells 
have also been shown to play their crucial roles in late phase allergic response and chronic , 
allergic inflammation by attracting T lymphocytes, neutrophils, basophils and eosinophils 
and promoting the T helper cell type 2 (Th2)-mediated inflammations [Marone et al, 2002]. 
Until the last two decades, human mast cell、have also been recognized in producing a 
wide spectrum of cytokines and chemokines. It consequently leads to the exploration of the 
21 
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both physiologic and pathologic roles of mast cell-derived cytokines and chemokines in 
diseases [He et al, 2004]. It is then revealed that mast cells are not only crucial for allergic 
responses, but also the non-allergic inflammations, innate and adaptive immunity [Woolley, 
2003; Pawankar et al, 2003]. There is now strong evidence showing the involvement of mast 
cells in a number of non-allergic diseases. For example, markedly increased number of mast 
cells was observed in the mucosa of the ileum and colon of patients with inflammatory bowel 
disease, which was accompanied by degraunulation of the content of mast cells. Pathogenesis 
of other non-allergic diseases including chronic obstructive pulmonary disease (COPD), 
Crohn's disease, ulcerative colitis, multiple sclerosis and rheumatoid arthritis, etc also shows 
mast cell is the key involved cell type. Table 1.1 shows the evidence of mast cells 
involvement in non-allergic diseases as adopted from He et al. 2004. 
Table 1.1. Mast cell involvement in non-allergic diseases 
Disease evidence 
chronic obstructive mast cell hyperplasia in eipithelia and bronchial glands, 
pulmonary disease (COPD) tryptase and histamine release in BALF 
Crohn's disease mast cell hyperplasia and degranulation 
ulcerative colitis mast cell hyperplasia and degranulation 
multiple sclerosis mast cell hyperplasia 
rheumatoid arthritis mast cell degranulation 
cystic fibrosis mast cell hyperplasia and degranulation in lung 
Recently, mast cells are also shown to be involved in innate and adaptive immunity. Mast 
cells show their role in innate immunity by recognizing specific molecular patterns from 
microbials through binding with Toll-like receptors and trigger inflammatory responses 
[Jeffrey et al, 2003]. C3a, one component of complement system that is essentially linked 
with innate immunity against bacteria and other pathogens, can also induce the release of 
餐 
chemokines form mast cells [Venkatesha et al, 2005]. Mast cells have also been shown to 
4 
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migrate from a site of antigen encounter, via afferent lymphatics to the draining lymph nodes, 
wherein they participate in induction of a primary immune response [Wang et al, 1998]. 
Together, mast cells are important effector cells in allergic responses, chronic allergic 
inflammation, non-allergic diseases and innate and primary immunity by releasing allergic 
mediators, cytokines and chemokines for autocrine and paracrine activation of the inflamed 
tissue [Walsh et al, 1991; Oliveira et al, 2001]. 
1.1.5 Human mast cell-1 (HMC-1) 
Mast cells are not normally found in human blood circulation and culture of mast cells 
from peripheral blood or inflamed tissues is very difficult and time consuming [Kimata et al, 
2000]. Therefore, investigation of human mast cells has been mostly relied on a human 
leukemic mast cell line (HMC-1) [Butterfield et al, 1998] as the in vitro mast cell model. 
Figure 1.2 shows the microscopic slide of HMC-1 cells using cytospin. HMC-1 is the mast 
cell line established from the peripheral blood of a patient with mast cell leukemia and 
retains the characteristic of immature mast cell expressing a low level of high affinity IgE 
(FcsRI) receptor. Detail phenotypic characterization has been done and shown to possess 
many characteristics of human mast cells including the expression of c-kit (SCF receptors) 
and the production of inflammatory mediators such as histamine, tryptase, leukotrienes and 
prostaglandins [Welker et al, 2001]. Table 1.2 shows the presence of mast cells markers in 
HMC-1 cells. HMC-1 is the only growth factor independent human mast cell line, and is well 
accepted to serve as an in vitro model to study basic mast cell functions and signal 
transduction [Kempna et al, 2004; Fitzgerald et al, 2004]. 
• 
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Figure 1.2 Photograph of HMC-1 cells under light microscope. The cells were centrifiiged at 
300 rpm for 3 min onto a microscopic slide using cytospin and then air-dried following by 
staining with Hemacolor rapid staining set. 
Table 1.2 The presence of mast cell markers on HMC-1 cells (adopted from Grabbe et al， 
1998) 
Parameter measured HMC-1 cells 
Tryptase (ng/10^ cells) 150 士 55 
FceRIa (high affinity IgE receptor, % of positive cells) 7.1 士 3.2 
Histamine (^ ig/lQ^ cells) 0.29 土 0.28 
c-kit (SCF receptor, % of positive cells) 79.0 士 9.3 
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1.2 Cytokines as stimulator of mast ceils in inflammation 
As mentioned in 1.1.3, mast cells can be activated by cytokines. Cytokines are small 
extracellular signaling proteins exerting effects by paracrine and autocrine manner, through 
the interaction with specific receptors on the surface of adjacent target cells or cells 
producing themselves. Some cellular functions initiated by cytokines include activation, 
proliferation, chemotaxis, release of other cytokines or mediators, cell differentiation, and 
apoptosis [Chung et al, 1999]. When inflammation occurs, cytokines produced by various 
cells act on each other to bring out the inflammatory responses. Human mast cells are shown 
to express the receptors for SCF, TNF-a, IL-13, IL-18 and IL-25, which play key roles in 
activating mast cells or conducting inflammatory responses after the stimulation of 
corresponding ligands [Wedi et al, 1996:. 
1.2.1 S C F 
SCF is a stromal cell-derived cytokine synthesized by fibroblasts in the peripheral tissue, 
eosinophils, airway smooth muscle cells, endothelial cells, and also mast cells themselves 
[Oliveria et al, 2003]. The receptor for SCF is the c-kit. The receptor has been associated 
with the activation of PI3-kinase, Akt and ERK pathways [Bondzi et al, 2000]. 
SCF is well known as a cytokine capable of regulating mast cell number and functions 
under physiological conditions. It is a growth factor that can induce differentiation and 
promote survival of mast cells [Oliveria et al, 2003]. At concentrations approximately 10-100 
fold lower than those eliciting cell proliferation, SCF promotes the synthesis of histamines 
and leukotriene C4 in mast cells [Oliveria et al, 2001]. Mast cells predominantly produce 
pro-inflammatory cytokines including IL-1, IL-^, IL-8, IL-16 and IL-18 in the presence of 
SCF [Lorentz et al, 2001]. It is also a potent chemotactic factor for mast cells by inducing 
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rearrangement of the actin filaments of the cytoskeleton [Gebhardt et al, 2005'. 
1.2.2 TNF-a 
TNF-a is produced from many cells including macrophages, T-cells, eosinophils, epithelial 
cells and also mast cells themselves, but the principal source is macrophages. TNF-a 
interacts through two related receptors, TNF-Pvl and TNF-R2. The two receptors have been 
identified to activate nuclear factor (NF)-KB, AP-1 and mitogen activated protein kinase 
(MAPK) intracellular signaling pathways [Chung et al, 1999:. 
TNF-a is an important mediator in many cytokine-dependent inflammatory events. It has 
been demonstrated to be capable of stimulating airway epithelial cells to produce different 
cytokines including RANTES, IL-8, and GM-CSF [Berkman et al, 1995; Cromwell et al, 
1992] in allergic asthma. It is known to up-regulate adhesion molecules such as E-selectin, 
intercellular adhesion molecule (ICAM)-l and vascular cell adhesion molecule (VCAM)-l in 
facilitating inflammatory cell migration [Thomas, 2001]. TNF-a can also act as a 
chemotactic cytokine for eosinophils and neutrophils [Ming et al, 1987]. 
1.2.3 IL-13 
IL-13 is expressed in activated CD4+ T-cells, CD8+ T-cells and mast cells. The receptor of 
IL-13 is IL-13 receptor that is expressed on macrophages, B-cells, eosinophils and mast cells 
[Wills-Karp, 2004]. 
IL-13 is a potent stimulator of inflammation and tissue remodeling that plays a key role in 
the pathogenesis of a wide variety of human disorders. IL-13 is a key inducer of several Th2 
cytokine-dependent pathologies. It regulates •inflammation, mucus production, tissue 
remodeling, and fibrosis [Mentink-Kane et al, 2004]. IL-13 induces human monocyte 
8 
Chapter 1 Introduction 
differentiation, enhances survival time in culture, and also induces B-cell differentiation, 
proliferation and isotype switching [Jelinek et al, 2000]. IL-13 down-modulates macrophage 
activity, reducing the production of proinflammatory cytokines (IL-1, IL-6, IL-8, IL-10, 
IL-12) and chemokines in response to IFN-y or bacterial lipopolysaccharides (LPS) 
[Wills-Karp, 2004]. IL-13 also decreases the production of nitric oxide by activated 
macrophages, leading to a decrease in parasiticidal activity, 
1.2.4 IL-18 
IL-18 is expressed by many cell types including monocytes and macrophages, T-cells, 
B-cells, mast cells, dendritic cells, intestinal epithelial cells [Dinarello, 1999; Nakanishi et al, 
2001] and its receptor is IL-18 receptor [Xu et al, 1998]. 
IL-18 is crucial in promoting Thl cytokine responses, primarily by its ability to induce 
interferon (IFN)-Y production in T cells, B-cells and natural killer (NK) cells. IL-18 can also 
up-regulate the cytotoxic actions of NK and CD8+ T cells by enhancing the expression of Fas 
ligand on their surfaces [Hoshino et al, 1999; Dao et al, 1996]. 
Though the importance of IL-18 in enhancing the Thl responses, several reports have 
shown its role in Th2 responses. A murine model of allergic asthma has illustrated that IL-18 
can augment allergic sensitization, serum IgE, Th2 cytokines, and airway eosinophilia [Wild 
et al, 2000]. Besides, the mRNA level of IL-18 was significantly increased in nasal mucosa 
after nasal allergen provocation in patients with allergic rhinitis [KleinJan et al, 1999]. 
1.2.5 IL-25 
IL-25 is secreted by bone marrow stromal cells, CD4+activated memory T cells and mast 
cells. Its receptor is IL-17 receptor homology 1 (Rhl) [Kawaguchi et al, 2004]. 
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IL-25 is a novel Th2 proinflammatory cytokine that can provoke allergic inflammation in 
atopic disease and late phase allergic reactions. Intranasal administration IL-25 induces 
eosinophilia in the bronchoalveolar lavage and lung tissue and increases the production of 
IL-4, IL-13 and eotaxin mRNA in the lung [Fort et al, 2001]. It has been shown that IL-25 
can induce chemokines and IL-6 release from eosinophils (Wong et al, 2005). Mice develop 
epithelial cell hyperplasia and airway hyperreactivity after intranasal administration of IL-25 
while knock out mice lacking IL-25 receptor do not develop eosinophilia in response to 
IL-25 [Hurst et al, 2002]. 
翁 
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1.3 Interaction of mast cells with inflammatory cells through adhesion molecules and 
chemokines 
Mast cells have been shown to interact with other inflammatory cells so as to mediate 
allergic and non-allegic inflammation. One of the earliest interaction with other cells is to 
bind with endothelial cells through cell surface expressed adhesion molecules, so that the 
mast cells can leave the blood circulation and enter the inflammatory sites [Pawankar et al, 
2003]. In fact, all the mast cell-mediated inflammations are characterized by an accumulation 
of mast cells in the inflamed tissue [Bischoff et al, 2002]. Within the inflammatory site, mast 
cells produce an array of mediators, cytokines or chemokines to activate or recruit other 
inflammatory cells [Frossi et al, 2004]. 
1.3.1 Adhesion molecules on mast cells 
ICAM-1 and ICAM-3 have been shown to be associated with recruitment of mast cells to 
inflamed tissues. Apart from their well recognized roles in leukocyte trafficking and 
cell-extracellular matrix adhesion, they can also transduce messages after binding with their 
ligands leading to degranulation or activation of the cells. 
(1) ICAM-1 
ICAM-1 is a 80 to 114 kDa calcium-independent transmembrane glycoprotein containing 
five Ig-like domains [Staunton et al, 1988]. Its ligands are lymphocyte function associated 
antigen-1 (LFA-1), macrophage antigen-1 (Mac-1), fibrinogen, hyaluronan and CD43 [van de 
Stolpe et al, 1996]. • 
ICAM-1 can be up-regulated in response to a variety of inflammatory mediators, including 
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proinflammatory cytokines, hormones, cellular stresses, and virus infection [Roebuck KA et 
al, 1999]. It is an important early marker of immune activation and involved in bronchial 
asthma, allergic rhinitis [Grzelewska-Rzymowska et al, 2004] and inflammatory bowel 
disease [Papa A et al, 2004]. Its interactions with the beta2 integrins LFA-1 and MAC-1 on 
the surface of leukocytes are important for their transendothelial migration to sites of 
inflammation and it also functions as costimulatory molecules for T cell activation [Roebuck 
KA et al, 1999]. It is also suggested that activated T cells mediate mast cell degranulation via 
ICAM-1-LFA-1 interaction [Inamura et al, 1998]. 
(2) ICAM-3 
Similar to ICAM-1, ICAM-3 also contains five Ig domains. The ligand is LFA-1 but not 
Mac-1 [Fawcett et al, 1992]. It is generally expressed at high levels on resting mast cells. 
ICAM-3 has been proposed to be an adhesion molecule that is particularly important in the 
initiation of immune responses, because of its higher level of constitutive expression on 
lymphocytes compared with ICAM-1 and ICAM-2 [de Fougerolles et al, 1994]. It has also 
been reported that engagement of ICAM-3 on monocytes and polymorphonuclear cells by 
specific immobilized mAbs induces secretion of chemokines and cellular spreading [Kessel 
et al, 1998]. Its ligation can lead to polymorphonuclear cell aggregation and adhesion to 
immobilized ligands [Feldhaus et al, 1998]. 
1.3.2 Chemokines released by mast cells 
Chemokines are a group of small (8 to 12 kDa) molecules able to induce chemotaxis in a 
variety of cells including neutrophils, monocytes., lymphocytes, eosinophils, fibroblasts, and 
keratinocytes. They are crucial during inflammatory responses for a timely recruitment of 
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specific leukocyte subpopulations [Moser et al, 2004]. Along with the accelerated rate of 
investigating the chemokines has come the realization that they not only control cell 
migration, but are also involved in a number of pathological processes through cell activation 
；Bisset et al, 2005]. 
Most chemokines have four characteristic N-terminal cysteines, and dependent on the 
motif displayed by the first two cysteines, they are classified into into four major groups 
given the preferred names CC, CXC, C and CX3C [Luster, 1998]. 
IL-8, interferon-inducible protein-10 (IP-10), RANTES, MCP-1, 1-309 and macrophage 
inflammatory protein have been shown to be released by mast cells and take 
different roles during inflammation [Selvan et al, 1994]. 
(1)IL-8 
IL-8 is a proinflammatory CXC chemokine binding to CXC chemokine receptor-1 and 2 
(CXCRl and CXCR2) which are mainly expressed on neutrophils. Significant correlations 
between plasma IL-8 concentration and neutrophil infiltration in acute inflammation has been 
reported [Huber et al, 1991]. 
Besides, IL-8 can regulate various biological functions of neutrophils including 
chemotaxis, degranulation, superoxide production, and expression of adhesion molecules. In 
eosinophil, IL-8 can induce shape change and release of eosinophil peroxidase from 
eosinophils of patients with hypereosinophilic syndrome [Kemen et al, 1991]. 
(2) MCP-1 
MCP-1 is a highly inducible inflammatory CC^chemokine. The effect of MCP-1 is exerted 
through receptor, CCR2, which is expressed on monocytes, T-cells, NK-cells, and basophils 
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but not eosinophils [Rollins, 2001:. 
Apart from the chemotactic properties, it enhances the proliferation response of naive 
T-cells to anti-CD3 and B7-1-induced costimulation [Taub et al, 1996], and has been reported 
to polarize naive T-cells toward Th2 responses when challenged by antigen [Karpus et al, 
1997]. As for monocytes, MCP-1 enhances adhesion by up-regulating several adhesion 
molecules including CD lib, CD 11c and CDl 8 [Vaddi et al, 1994]. In addition, MCP-1 can 
mediate inflammatory response by stimulating IL-1 and IL-6 expression from monocytes and 
histamine release from basophils [Kuna et al, 1992]. 
(3) RANTES 
RANTES is a CC chemokine binding to CCRl, CCR4 and CCR5 receptors which are 
expressed on T-cells, monocytes, eosinophils and basophils. Therefore, RANTES is 
chemotactic for these cell types and plays an active role in recruiting leukocytes into 
inflammatory sites [Zhang et al, 1994]. 
RANTES also activates eosinophils to release, for example, eosinophilic cationic protein 
making it often associating with diseases such—as asthma and allergic rhinitis [Lampinen et al, 
2004]. It also increases the adherence of monocytes to endothelial cells [von Hundelshausen 
et al, 2004]. RANTES activates human basophils to release histamines [Conti et al, 1997]. 
(4) IP-10 
IP-10 is a CXC chemokine. Its effect is mediated through the CXCR3 receptor that is 
expressed on Thl cells, monocytes and neutrophils. Therefore, IP-10 selectively 
chemoattracts Thl cells, monocytes and neutrophils [Zeng et al, 2005]. Increased levels of 
IP-10 are found in psoriatic plaques characterized by the infiltration of neutrophils [Gottlieb 
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et al, 1988]. 
IP-10 also takes up roles other than chemotaxis by inhibiting cytokine-stimulated 
hematopoietic progenitor cell proliferation. Additionally, it is angiostatic and mitogenic for 
vascular smooth muscle cells [Yang et al, 2004]. It has also been suggested that IP-10 may 
play an important role in hypersensitivity reactions of the delayed type [Akahira-Azuma et al, 
2004]. 
(5) 1-309 
1-309 is a CC chemokine that can act through the CCR8 receptor which is expressed on 
monocytes and Th2 cells [Haque et al, 2001]. It therefore chemoattracts these cell types and 
favors Th 2-associated allergic reactions [D'Ambrosio et al, 1998]. 
1-309 also exhibits an anti-apoptotic activity. The overexpression of this chemokine 
inhibited apoptosis in adult T-cell leukemia cells and can substantially contribute to their 
growth [Ruckes et al, 2001]. It can also protect thymic lymphomas against corticoid-induced 
apoptosis [Louahed et al, 2003]. 
(6) MIP-ip 
MIP-1(3 is a CC chemokine. It exerts its effect through CCRl and CCR5 [Rossi et al, 
2000]. MIP-IB preferentially attracts CD4+ T cells [Taub et al, 1993]. 
It is also involved in the cell activation of human granulocytes (neutrophils, eosinophils, 
and basophils) and appears to be involved in acute neutrophilic inflammation [Schall et al, 
1993]. It can also augment the adhesion of CDS + T-celis to the VCAM-1 and it does so by 
being present on the surface of endothelial cells complexed with endothelial proteoglycans 
[Tanakaet al, 1993]. 
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1.4 Intracellular signaling pathways in mast cells 
Recently, there have been increasing interests in the elucidation of the regulatory 
mechanisms of mast cell activation, differentiation, chemotaxis, adhesion, cytokine and 
chemokine productions and degranulation. One way to demonstrate the regulatory 
mechanisms is to study the activation of different signal transduction pathways under 
different stimulations. Signaling pathways direct the cellular functions by transducing the 
messages from the membrane receptors through a stream of signaling molecules, in which 
activated p38-mitogen-activated protein kinases (MAPK), extracellular-regulated protein 
kinase (ERK) and nuclear factor-kappa B (NF-KB) have been shown to regulate 
inflammatory responses [Wong et al, 2004]. 
1.4.1 The p38 MAPK pathway 
p38 MAPK has been shown to be an important regulator of inflammation [Sundstrom et al, 
2003] by regulating the cellular degranulation, chemotaxis, and adhesion molecules in 
allergic inflammation. Besides, its activation mediates inflammatory cell adhesion by 
inducing the expression of different adhesion molecules such as ICAMs and VCAMs [Johns 
et al, 2005]. The p38 MAPK is also an important mediator of the cellular response to 
environmental stress. It is activated by osmotic stress, UV irradiation, ionizing radiation, 
bacterial cell wall product LPS, and various proinflammatory cytokines including TNF-a and 
IL-ip (Raingeaud et al, 1995; Kyriakis & Avruch, 2001). Besides, it helps in regulating other 
physiological processes including cell cycle progression, differentiation and apoptosis. 
Upon activation, p38 MAPK is subjected to dual phosphorylation at the Thr-Gly-Tyr motif. 
The phosphorylated p38 then activates a variety of transcription factor including activating 
transcription factor (ATF)-2, signal transducer and activators of transcription (Stat)-l, 
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Max/Myc complexes, MEF-2A/C, Elk-1 and cAMP responsive element binding protein 
(CREB). On the other hand, the upstream kinases acting on p38 include MAPK kinases 
(MKK) 3 and 6 which are in turn activated by MAPK/ERK kinases (MEKKs), MLKs and 
ASKl [Roux et al, 2004]. Figure 1.3 shows the signaling pathway of p38 and the inhibitor 
SB 203580 that can inhibit the kinase activity of p38 MAPK. 
1.4.2 The ERK pathway 
ERK pathway has been well known for its involvement in cell proliferation, movement, 
and differentiation [Eblen et al, 2002, Hashimoto et al, 2000]. The ERK is shown to be 
activated by growth factor like IL-5 for the regulation of cell proliferation, transformation 
and differentiation [de Groot et al, 1998]. Recently, ERK activation is also found to be 
related to inflammations. Its inhibition can inhibit lung inflammation using a murine asthma 
model by suppressing the production of Th2 cytokines [Chialda et al, 2005]. Activation of 
ERK can also induce the release of chemokine IL-8 from neutrophils in inflammatory 
responses [Jo et al, 2004]. 
ERK functions downstream of the ras oncogene. Ras is activated in response to agonist 
stimulation and recruits Raf protein kinases to the plasma membrane [Leevers et al, 1994], 
where Raf undergoes activation by a mechanism that is incompletely understood. Raf 
proteins phosphorylate and activate ERK kinases (MEKs), which phosphorylate and activate 
the two ERK proteins, ERKl and ERX2. MEKs can serve as cytoplasmic anchors for the 
ERKs through a direct binding interaction, holding the ERKs in the cytoplasm at times when 
the signaling pathway is inactive [Fukuda et al, 1990]. Stimulation of the pathway results in 
the phosphorylation of the ERKs and their dimerization and translocation to the nucleus and 
other sites of action, where they phosphorylate transcription factors e.g. Elk-1, Stat 1 and 4, 
c-myc and ER for bringing out biological responses [Eblen et al, 2002]. Figure 1.4 shows the 
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signaling pathway of ERK. PD98058 is the selective and cell permeable inhibitor of MAPK 
kinase (MEK) that acts by inhibiting the activation of ERX and subsequent phosphorylation 
of substrate. 
1.4.3 The NF-KB Pathway 
NF-KB is a ubiquitous transcription factor that appears to be of particular importance in 
cytokine-mediated inflammatory and immune responses. Activation of NF-KB can enhance 
the transcription of a variety of genes, including cytokines and growth factors, adhesion 
molecules, immunoreceptors, and acute-phase proteins [Blackwell et al, 1997]. It is highly 
activated at inflammation tissues in various diseases including allergic asthma by enhancing 
the recruitment of inflammatory cells and production of pro-inflammatory cytokines [Ip et al, 
2003]. Inhibition of NF-KB activity is effective at controlling inflammatory diseases in 
several animal models [Wong et al, 2003]. 
In unstimulated cells, NF-KB is localized to the cytoplasm because of binding to inhibitory 
protein, IKB [Baldwin, 1996]. When the cell is activated, specific IKB kinase phosphorylate 
IKB, leading to the rapid addition of ubiquitin and subsequent degradation in proteasome by 
the action of protease [Baldwin, 1996]. This allows NF-KB to be transported to the cell 
nucleus, where its dimers are free to bind to specific motifs in the promoter regions of 
various genes, and initiate transcription. Figure 1.5 shows the signaling pathway for NF-KB. 
BAYl 17082 can selectively and inreversibly inhibit the phosphorylation of IKB-CC, resulting 
in a decreased expression of NF-KB. 
1.4.4 Cross-talking of pathways 
In 1.4.1, 1.4.2 and 1.4.3, p38 MAPK, ERK and NF-KB pathways were illustrated as 
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separate mechanisms starting from the membrane receptors, series of kinases and ultimately 
to transcriptional factors. However, signaling pathways are never discrete pathways but 
interact to from an integrated network by which precise and coordinated biological responses 
are given out. 
A previous report has demonstrated that p38 MAPK is required for NF-KB-dependent 
expression of cytokines genes by the modulation of DNA binding of TATA—binding protein 
to the TATA box [Carter et al, 1999]. Inhibition of p38 MAPK can therefore potentially 
attenuate NF-KB-dependent transcription [Heinrich et al, 2000]. The two MAPK pathways, 
p38 and ERK, facilitate their cross-talking through scaffold proteins and adaptor molecules. 
Several MEK family members contain sites that can be phosphorylated by other kinases in 
p38 MAPK so that integration of signals can occur [Underwoon et al, 2000]. Moreover, Jiang 
et al [2002, 2004] demonstrated that ERK activity is required for persistent NF-KB activation 
and revealed a novel functional role for ERK as an important temporal regulator of NF-KB 
activation and NF-KB-dependent gene expression. 
m 
19 






(MKK 3 / 6 � 
i ^ S B 2 0 3 5 8 0 
|p38 MAP^^ 
cytoplasm 
e / degranulation 
^ / chemotaxis 
卜 / d — i a t i o n 
\ ^ / |CREB^  / apoptosis 
—lif— £ _ 
r cytokine synthesis 
Figure 1.3 The p38 MAPK signaling pathway. SB 203580 is the potent selective p38 MAPK 
inhibitor. 
2 0 











、y I 1 
nucleus f ^ R K 1 / 2 / cell proliferation 
• Z 喜 念 ^ _ ^_^ / movement ERK 1/2 / 
^ ^ ^ ^ � � ” . � 1 / differentiation 
Figure 1.4 The ERK signaling pathway. PD98058 is the selective inhibitor of MEK. 
2 1 
Chapter 1 Introduction 
Receptor 
C -N 
B A Y 1 1 7 0 8 2 
Proteosomal ^^•叛 




Figure 1.5 The NF-KB signaling pathway. BAY117082 can inhibit the IKB kinase and hence 
the subsequent phosphorylation of IicB-a 
22 
Chapter I Introduction 
1.5 Signal transduction pathways and pharmacological interventions 
As mentioned, p38 MAPK, ERK and NF-KB can act as the key regulators in coordinating 
genes that control immune responses [Dong et al, 2002; Pomerantz et al, 2002]. ERK and 
p38 MAPK transduce growth and differentiation signals and mediate inflammatory and stress 
responses [Kyriakis et al, 2001]. The constitutive activation of NF-KB pathway has been 
shown to correlate with inflammatory diseases, such as rheumatoid arthritis, inflammatory 
bowel disease and allergic asthma [Li et al, 2002]. Intracellular signaling molecules can 
therefore conduct pathological consequences and inhibition of these pathways may have 
implications for treating inflammatory diseases [Kowalski et al, 2001]. 
The past few years have witnessed a remarkable increase in understanding of the details of 
signaling events stimulated by various cytokines and growth factors. This advance makes 
pharmacological intervention be possible in different levels throughout signal transduction 
cascade [Tas et al, 2005]. There are agents which directly affect cytokine or growth factor 
receptor function by binding and acting as agonists or antagonists or by inhibiting the 
receptor associated enzymatic activity. Some agents inhibit intermediate steps between the 
receptor and transcription, including protein kinases and phosphodiesterases [Saklatvala et al, 
2004]. Others bind to transcription factors directly and modulate their activity [Young, 1998]. 
Several pharmacological agents have now been established for showing effects on several 
signaling pathways. Table 1.2 shows the compounds that can affect signal transduction with 
the mode of actions and possible therapeutic use (adapted from Young, 1998 and Wong et al, 
2004). 
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Table 1.2. Possible therapeutic use of signaling pathway inhibitors 
Molecular target compound Mode of action therapeutic use 
p38 MAPK SB 203580 Inhibit kinase Anti-inflammatory 
MEK PD 98059 Inhibit kinase Cancer metastasis, 
U0126 ischemia, 
anti-inflammatory 
PI3 kinase Wortmannin Inhibit kinase Inhibit neutrophil 
function 
JAK2 Tryphostin Inhibit kinase Anti-cancer 
TOR Rapamycin Inhibit kinase Immunosuppression 
Epo receptor EMPl Antagonist Anemia, acute renal 
failure 
CCRl receptor 4-hydroxy piperidines Antagonist Multiple schlerosis, 
rheumatoid arthritis 
IL-1 receptor AF12198 Antagonist Anti-inflammatory 
CXCR2 receptor SB 225002 Antagonist Reperfusion injury, 
一 anti-inflammatory 
In future, with the advance in elucidation of the molecular and cellular mechanisms of 
inflammatory diseases, the signal transduction mechanisms of inflammatory cascades will 
certainly provide more new potential therapeutic strategies. 
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1.6 Traditional Chinese medicine (TCM) and pharmacological intervention 
In the above section 1.5, we have introduced one way of exploring therapeutic intervention, 
i.e. inventing chemicals to block certain pathological routes through understanding the 
molecular mechanisms. However, there is another means to explore efficient treatments 
through a vice versa way; by starting from a substance that has shown efficacy in treating a 
disease without knowing its mechanisms. TCM has a long history in treating various diseases 
and been showed to improve general well being by enhancing and modulating immunity. 
TCM efficacy has been proved by millions of clinical trials started from thousands of years 
ago when it was firstly administered in human beings. TCM has now become a new trend in 
pharmaceutical development especially in treating chronic and age-related diseases. 
Well-planned in vitro, animal and clinical research studies have been carrying out by 
different research groups to elucidate the mechanisms by which TCM exerts it effects on 
different diseases. 
1.6.1 Anti-allergic activities of traditional Chinese medicine 
One of the chronic diseases, asthma, has attracted researchers particular attention in 
revealing the TCM efficacy on its treatment. Asthmatic patients now realize that the two 
major therapies for asthma, p2-adrenoceptor (P2AR) agonists and inhaled corticosteroids 
(Barnes, 2002) can lead to metabolic, endocrine and systemic adverse effects in long term 
use. A survey by the National Asthma Campaign found that 60% of people with moderate 
asthma and 70% with severe asthma in USA have used complementary and alternative 
medicine to treat their condition so as to compensate the side effects [Huntley et al, 2000]. 
TCM is the third most popular choice complementary medicine of both adults (11 %) and 
翁 
children (6%) suffering from asthma [Ernst, 1998]. Therefore, it is an urgent need to 
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demonstrate the anti-allergic effects of TCM, which is thought to be associated with fewer 
side effects and has been widely prescribed by asthmatic patients, through adequately 
designed clinical trials or in vitro studies. 
Recently, many publications have provided evidence of TCM in prevention or treatment of 
asthma. For example, the antiasthmatic effects of Xiao-qing-long-tang (XQLT,小青育直湯） 
appear to be partly mediated by stimulation of p2-adrenoceptors, leading to 
bronchorelaxation, and that XQLT inhibits the infiltration of eosinophils into the airway [Kao 
et al, 2001]. Oral administration of Bu-Zhong-Yi-Qi-Tang (辛甫中益氣湯）can suppress IgE 
antibody production and histamine release in type I allergic reaction in mice immunized 
intraperitoneally with a mixture of ovalbumin and aluminium hydroxide [Suzuki et al, 1999]. 
Therapeutic activity of Cordyceps sinensis in treating asthma is shown to be related to the 
modulation of Thl and Th2 cell functions in bronchial airway by suppressing IL-lp, IL-6 and 
TNF-a production in bronchoalveolar lavage fluids (BALF) cells [Kiio et al, 2001]. 
1.6.2 Investigation of the in vitro anti-allergic activities of a newly developed Wheeze-Relief 
Formula 
In promoting the modernization of TCM and providing clinical research for drug 
development, a consortium, led by The Chinese University of Hong Kong with close 
collaboration from the City University of Hong Kong, The Hong Kong Polytechnic 
University and The Hong Kong University of Science and Technology, was formed. The 
consortium adopts an efficacy driven approach and establish an evidence-based scientific 
model for TCM research. One of the priority projects conducted by this consortium is to 
prove the efficacy of a selected herbal formula on childhood asthma. In Hong Kong, asthma 
is the commonest chronic disease affecting children. The prevalence was 6.0% in children 
between 3 and 10 years of age in Hong Kong and 11% in 13 and 14 years old age Group 
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！Leung et al, 1997]. In Hong Kong, between 1992 and 1995，the lifetime prevalence of 
asthma and wheeze in school children increased from 6.6% to 11.2% and from 3.7% to 
12.40/0, respectively [Leung et al, 1997]. To combat this chronic disease with increasing 
prevalence, a Wheeze-Relief formula has been designed by Chinese Medicine practitioner. 
This Wheeze-Relief formula consists of five herbal components, including Cordyceps 
sinensis (冬蟲夏草，Dong Chong Xia Cao), Bulhus Fritillariae cirrhosae (J【l貝，Chuan Bei), 
Radix Stemonae (百音P, Bai Bu), Radix astragali (黃耆，Huang qi) and Radix Scutellariae 
(黃夸,Huang qin). They are common ingredients in many patent Chinese cough mixtures for 
treating chronic bronchitis. They are also well known to relieve symptoms of many 
respiratory diseases. 
Cordyceps sinensis is traditionally considered as a tonic to nourish the lungs and kidneys. 
This herb has an antiasthmatic effect by causing smooth muscle relaxation and potentiating 
the epinephrine effects. It can also exhibit an immunopotentiating effect in treating cancer 
and immunodeficient patients [Kuo et al, 2001]. 
Bulbus Fritillariae cirrhosae is a good antitussive agent that is used to relieve coughing 
and dyspnea, in case of chronic bronchitis or upper respiratory infection. It can cause 
bronchodilation and inhibition of mucosal secretions [Huang et al, 1999]. 
Radix Stemonae can suppress excitation of the respiratory center and inhibit the coughing 
reflex. It also exerts antituberculous, antibacterial and antifungal effects [Liao et al, 1997]. 
Radix astragali is an important herb in TCM to treat common cold and influenza. The 
polysaccharide of the herb has antirhinoviral activity and can promote and potentiating 
interferon functions on antiviral activity [Shon et al, 2002]. 
Radix Scutellariae has antibacterial and antiviral activity. This herb and its active principle, 
baicalin, are used in the treatment of upper respiratory infections, such as acute tonsillitis and 
acute laryngopharyngitis [Liao et al, 2003; and Huang et al, 1999]. 
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In our laboratory, in vitro investigation and drug authentication using this Wheeze-relief 
formula were carried out in the past few years. We have shown that the anti-asthmatic effects 
may be brought out by immunomodulation on eosinophils and PBMC. 
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1.7 Scope and aims of the study 
As mentioned in 1.1.4, mast cells assume multiple roles in body immunity. They are 
central effector ceils of immediate-type hypersensitivity such as allergic asthma and atopic 
rhinitis. They are also involved in T helper (Th) cells -mediated inflammation such as 
inflammatory bowel disease [He et al, 2004] and rheumatoid arthritis [Woolley et al, 2003], 
as well as both natural and acquired immunity [Marone et al, 2002]. An accumulation of mast 
cells in the inflammatory sites is observed in all the mast cell-mediated inflammatory 
reactions [Bischoff et al, 2002]. Besides, under the effects of cytokines in the inflamed 
tissues, mast cells mediate the recruitment of different subpopulation of leukocyte by 
producing different chemokines [Selvan et al,1994]. 
Therefore, the regulation of recruitment of mast cells and also their interaction with other 
inflammatory cells have essential importance in the mechanism of inflammation [Fitzgerald 
et al, 2004]. However, the underlying mechanisms in recruiting mast cells from the 
circulation through their cell surface-expressed adhesion molecules are still poorly defined. 
The interaction of mast cells with other inflammatory cells either through direct intercellular 
adhesion or paracrine activation is also largely not clarified. To more clearly elucidate the 
functions of mast cells in inflammation, expression of adhesion molecules and chemokines of 
human (HMC-1) mast cells after cytokine stimulations was studied. 
SCF, TNF-a, IL-13, IL-18 and IL-25, which play key roles in activating mast cells or 
conducting inflammatory responses (mentioned in 1.2)，were used to stimulate HMC-1 cells. 
The expression of cell surface-expressed adhesion molecules, ICAM-1 and ICAM-3, was 
then assayed. They have been shown to be associated with mast cell trafficking and 
transduction of messages to other cells after binding with their ligands (mentioned in 1.3.1). 
The release of chemokines including IL-8, IP-10, RANTES, MCP-1,1-309 and MlP-ly^ from 
HMC-1 cells after the cytokine stimulation was also studied. All these chemokines have been 
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shown to be released by mast cells and take different roles during inflammation (mentioned 
in 1.3.2). With the results obtained, we could then more clearly define the biological and 
pathological roles of mast cells in inflammation. Certain therapeutic strategies in treating 
mast cell-related diseases may also be devised. 
To further understand the mechanisms in regulating the responses of mast cells under the 
effects of different cytokines, the activation of three intracellular signal transduction 
pathways including p38 MAPK pathway, ERK pathway and NF-KB pathway was studied. 
These three signaling pathways have been shown to play important roles in regulating 
inflammatory responses (mentioned in 1.4). ERK pathway inhibitor PD98059, p38 MAPK 
pathway inhibitor SB203580 and NF-KB pathway inhibitor BAY 117082 were also used to 
elucidate which signaling pathway is responsible for a specific cytokine-induced response. 
Apart from getting important information in understanding the pathological consequences 
mediated by these intracellular signaling molecules, we could also generate pharmacological 
implications for treating inflammatory diseases. 
At last, to further reveal the roles of mast cells in immunity, we used a membrane array to 
simultaneously profile 96 genes associated with inflammatory responses. The array could 
give information on the expression of cytokines, chemokines and their receptors on HMC-1 
cells. It could then provide much information in deducing the functions of mast cells in 
inflammations. 
Another part of my study was to investigate the in vitro anti-allergic activities of a 
Wheeze-relief formula comprised by five herbal components, including Cordyceps sinensis, 
Bulbus Fritillariae cirrhosae. Radix Stemonae, Radix astragali and Radix Scutellariae. The 
results obtained in the first part of study, i.e. the cytokine-induced responses of mast cells, 
were used to develop immunological parameters in assessing the potential anti-allergic 
activities of the formula. Experiments were performed to reveal whether the addition of the 
five herbs could or could not suppress the effects of cytokines on HMC-1 cells. 
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Chapter 2 
Materials and Methods 
2.1 Materials 
2.1.1 HMC-1 cell Line 
HMC-1 cells were a generous gift from Dr. J. H. Butterfield of the Mayo Clinic, 
Rochester, MN, USA. It is a human mast cell line established from the peripheral 
blood of a patient with mast cell leukemia. 
2.1.2 Media and reagents for cell culture 
(1) Culture medium 
Iscove's Modified Dulbecco's Medium (IMDM) containing L-glutamine and 
supplemented with sodium bicarbonate at pH 7.2 was used to culture HMC-1. This 
culture medium was purchased from Gibco Invitrogen Corp, CA, USA. 
(2) Serum supplements 
Fetal calf serum (FCS) was purchased from Hyclone Co, MA, USA. It had been 
tested with low endotoxin (<10 EU/ml) and hemoglobin (<10 mg/ml) level. 
Heat-inactivated fetal calf serum (HI-FCS) was prepared as 50 ml aliquots by heating 
m 
at for 30 minutes and stored at -20°C until use. 
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(3) Phosphate-buffered-saline (PBS) solution 
Sterilized PBS solution (0.2 g potassium chloride, 8 g sodium chloride and 1.15 g 
dibasic sodium phosphate in 1 L) at pH 7.4 was purchased from Gibco Invitrogen 
Corp. 
(4) Endotoxin-free solution 
Cell culture medium which was free of detectable LPS (<0.1 EU/mL) was 
purchased from Gibco Laboratories, Grand Island, NY, USA. All other solutions were 
prepared using pyrogen-free water and sterile polypropylene plasticware. No solution 
contained detectable LPS, as determined by the Limulus amoebocyte lysate assay 
(sensitivity limit 12 pg/ml; Cambrex Bio Science Walkersville Inc, MD, USA) 
2.1.3 Recombinant human cytokines 
(1) Recombinant human SCF and TNF-a 
SCF and TNF-a (Pepro Tech EC Ltd, London, UK) were a lyophilized recombinant 
protein derived from Escherichia coli {E. coli) with specific activity of > 2 x 10^  
units/mg. It was reconstituted in autoclaved distilled water to 20 |Lig/ml in sterilized 
IMDM medium supplemented with 2% HI-FCS. It was kept as 50 |u.l aliquots 
at -80°C until use. 
(2) Recombinant human IL-13, IL-18 and IL-25 
IL-13, IL-18 and IL-25 were purchased from Medical & Biological Laboratories 
Co Ltd, Nagoya, Japan. It was a lyophilized recombinant protein derived from E. coli. 
Each cytokine was reconstituted 10 ).Lg/ml in sterilized PBS supplemented with 0.5% 
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BSA. Twenty jLil aliquots were kept at -80°C until use. 
2.1.4 Signal transduction pathway inhibitors: PD98035, SB203580 and BAYl 17082 
These were purchased from Calbiochem, San Diego, California, USA. SB 
203580 •HCl is a pale yellow solid which is a water-soluble form of the potent 
selective p38 MAP kinase inhibitor. PD98058 is a pale yellow solid which is a 
selective and cell permeable inhibitor of MAP kinase kinase (MEK) that acts by 
inhibiting the activation of MAP kinase and subsequent phosphorylation of MAP 
kinase substrate. BAY 117082 is an off-white crystalline solid that can selectively and 
irreversibly inhibit the IKB kinase and hence the subsequent phosphorylation of IKB-OI, 
resulting in a decreased expression of NF-KB. PD98058 and BAYl 17082 were 
dissolved in dimethyl sulfoxide (DMSO). In all studies, the concentration of DMSO 
was 0.1 % (vol/vol). SB 203580 was reconstituted in distilled water to 10 mM. 
Aliquots of inhibitors were stored at -80°C until use. 
2.1.5 Monoclonal antibodies and reagents for immunofluorescent staining 
(1) Monoclonal antibodies (mAb) 
FITC-conjugated mouse IgGi anti-human ICAM-1 (CD54) mAB (clone BBIG-Il) 
was purchased from R & D System Inc, MN, USA. FITC-conjugated mouse IgG2b 
anti-human ICAM-3 (CD50) mAB (clone TU41), rat IgGia immunoglobulin isotype 
control and mouse IgGi immunoglobulin isotype control were purchased from BD 
Pharmingen Corp, CA, USA. . 
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(2) Human Serum 
Human serum for blocking procedure in immunofluorescent staining was obtained 
from venous blood of Chinese healthy volunteers. 
(3) FACSFlow sheath fluid 
It is a balanced electrolyte solution containing sodium chloride, potassium chloride, 
disodium EDTA, sodium fluoride and anti-microbial agent. The solution was 
purchased from BD Bioscience Corp, CA, USA. 
(4) FACS medium 
The buffer contains 0.5% BSA and 0.01% sodium azide (NaNs) in IX PBS. It was 
used for washing in immunofluorescent staining. 
(5) 1 % paraformaidehye 
Paraformaldehyde powder (10 g) (Sigma Chemical Co, MO, USA) was dissolved 
in 1 L IX PBS for cell fixation. 
2,1.6 Reagents and buffers for chemokine detection 
(1) Cytometric Bead Array (CBA) kit 
Chemokine Human CBA kit I for measurement of IL-8, RANTES, MIG, MCP-1 
and IP-10, was purchased from BD Pharmingen Corp. The kit contains cytometer 
setup beads, PE positive control detector, FITC positive control detector for 
compensation settings. It also contains five populations of capture beads, PE 
翁 
conjugated detection reagents, standards and wash buffer for chemokine detection. 
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(2) ELISAfor 1-309 and MIP-1(3 
The ELISA kits were purchased from R & D Systems Inc. These assays employ the 
quantitative sandwich enzyme immunoassay technique. The kits contain either a 
microplate pre-coated with monoclonal antibody specific for 1-309 or MIP-ip, a 
secondary antibody that is conjugated to horseradish peroxidase and also a 
tetramethylbenzidine (TMB) substrate. 
2.1.7 Reagents and buffers for Total RNA Extraction 
(1) DNase/RNase-Free DEPC-treated Distilled Water 
Double distilled water was treated with 0.1% diethyl pyrocarbonate (DEPC) 
(Sigma Chemical Co), and shaken thoroughly to disperse the DEPC. After standing 
overnight, the solution was then autoclaved at 121 for 15 minutes. 
(2) Qiagen RNeasy® Total RNA Extraction Kit 
The kit purchased from Qiagen GmbH, Hilden，Germany, was used to extract RNA. 
It consisted of a guanidine isothiocyanate* containing lysis buffer RLT for cytolysis, 
RNeasy spin columns for RNA capture, wash buffers RWl and RPE for RNA 
precipitation and washing, and RNase-free water for RNA elution. Each RNeasy spin 
column had a binding capacity of 100 
(3) P-Mercaptoethanol (2-ME) 
Stock solution of 2-ME was purchased from Sigma Chemical Co. In 1ml lysis 
buffer of Qiagen RNeasy® total RNA extraction kit, 10 |LII of 2-ME was added prior 
幽 
to cell lysis. 
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(4) RNase-Free DNase Set 
The DNase set (Qiagen GmbH) contained RNase-Free DNase I (2500 Kunitz 
units/mg), RNase-Free buffer and water. It was used for on-column digestion of 
contaminated genomic DNA during RNA purification using RNeasy Total RNA 
extraction kit. 
2.1.8 Reagents and buffers for Reverse Transcription — Polymerase Chain Reaction 
(RT-PCR) 
(1) First-strand cDNA synthesis kit 
The kit was purchased from Amersham Biosciences Corp and stored at -20 It 
consisted of the following components: 
a. Bulk First-Strand cDNA Reaction Mixes: Cloned, FPLCpure⑧ Murine 
Reverse Transcriptase, RNAguard (porcine), RNase/DNase-Free BSA, dATP, 
dCTP，dGTP, and dTTP in aqueous buffer. 
b. DTT Solution: 200 mM aqueous solution. 
c. pd(N)6 Primer: Random hexadeoxynucleotides at 0.2 fig/jiil. 
d. Not I-d(T)i8 Bifunctional Primer: 5’ d[AAC TGG AAG AAT TCG CGG 
C C G C A G G A A T I 8 ] - 3 , at 5 JIG/^ IL. 
e. mRNA Standard: Synthetic mRNAs; 1 fig in aqueous solution at 50 \ig/m\, 
f. DEPC-treated RNase-Free Water 
(2) AmpliTaq Gold™ with GeneAmp® lOX PGR buffer and MgCh solution 
AmpliTaq Gold DNA polymerase (250 units, 5 U/|al), 10 x PGR reaction buffer 
m 
[100 mM Tris-HCl，pH 8.3, 500 mM KCl, 15 mM MgCh, 0.01% (w/v) gelatin] and 
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25 mM MgClz solution were all from Perkin Elmer Corp, CA., USA, and stored at -20 
"C. 
(3) Primers 
The PCR primers specific for different human genes were purchased from Gibco 
Invitrogen Corp. The lyophilized primers were reconstituted in TE buffer to obtain a 
stock at a concentration of 100 pmoles/jjl The stocks were aliquoted and kept 
at -20°C. The primer sequences, annealing temperatures, and their PCR product sizes 
were as follows: 
Human ICAM-1 
Sense: 5'-CGT GCC GCA CTG AAC TGG AC-3’ 
Anti-sense: 5'-CCT CAC ACT TCA CTG TCA CCT-3' 
Annealing temperature: 60°C 
PCR product size: 447-bp 
Human IL-8 
Sense: 5’-CTG TGT GAA GGT GCA GTT TTG CC-3’ 
Anti-sense: 5'-CTC AGC CCT CTT CAA AAA CTT CTC C-3' 
Annealing temperature: 55°C 
PCR product size: 237-bp 
Human IP-10 
Sense: 5'- CCT GCT TCAAAT ATT TCC CT -3' 
Anti-sense: 5'- CCT TCC TGT ATG TGTTTG GA -3' 
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Annealing temperature: 55°C 
PGR product size: 229-bp 
Human MCP-1 
Sense: 5'- AAT GCC CCA GTC ACC TGC TGT TAT -3’ 
Anti-sense: 5'- GCAATT TCC CCAAGT CTC TGTATC -3' 
Annealing temperature: 55°C 
PGR product size: 427-bp 
Human RANTES 
Sense: 5,-ATATTC CTC GGACAC CAC AC -3’ 
Anti-sense: 5'- CAC GTC CAG CCT GGG GAA GG -3' 
Annealing temperature: 55°C 
PGR product size: 370-bp 
Human 1-309 
Sense: 5,-GCC CAA GCC AGA CCA GAA GAC A -3’ 
Anti-sense: 5'-AAG CAG GGC AGA AG AAT GGT G -3' 
Annealing temperature: 65°C 
PGR product size: 403-bp 
Human MIP-1(3 
Sense: 5'-TAG CAT GAA GCT CTG CGT GAC T -3' 
Anti-sense: 5,-ATT A AG AGA AGG GAC AGG AAC T-3' 
m 
Annealing temperature: 55°C 
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PCR product size: 400-bp 
Human (3-actin 
Sense: 5’-AGC GGG AAATCGTGC GTG-3' 
Anti-sense: 5’-CAG GGTACATGG TGG TGC C-3' 
Annealing temperature: 60°C 
PCR product size: 300-bp 
(4) PCR nucleotide mix 
It was a premixed solution containing sodium salts of dATP, dCTP, dGTP and dTTP, 
each at a concentration of 10 mM in water at pH 7.5. The mixture was purchased from 
Promega Corp, Madison, WI, USA and stored at -20 
(5) TE Buffer 
This consisted of 10 mM Tris-HCl (pH 7.5) and 0.1 mM EDTA in distilled water. 
The solution was used for cDNA dilution and kept at room temperature. 
2.1.9 Reagents and Buffers for Protein Extractions 
(l)RIPAcell lysis buffer 
It was bought from Assay Designs Inc, MI, USA and contains 50 mM Tris-HCl, pH 
7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2 mM sodium orthovanadate, 20 mM 
sodium pyrophosphate, 1 % Triton X-100, 1 % sodium deoxycholate, 0.1 % SDS and 
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1 X protease inhibitors. The cell lysis buffer was used to extract total proteins for 
Western blot analysis and kept as 5 ml aliquots at -80°C. 
(2) NE-PERTM Nuclear and cytoplasmic extraction kits 
This was purchased from Pierce Biotechnology Inc, IL, USA. It supplied a 
complete set of cytoplasmic and nuclear extraction reagents that enabled the 
separation of non-denatured and active proteins of nuclear extract and cytoplasmic 
fraction from cultured cells and tissue. It contains cytoplasmic extraction reagent I 
(CER I) and cytoplasmic extraction reagent II (CER II) for lysing the cell membranes 
and release of cytoplasmic contents and nuclear extraction reagent (NER) for lysing 
the nuclei. It was stored at 4°C and used to extract nuclear protein for NF-KB activity 
assay. 
2.1.10 Reagents and buffers for detection of activated signaling pathways 
(1) Micro BCA Protein Assay Kit 
The kit was purchased from Pierce Biotechnology Inc and used to determine the 
concentration of proteins. 
(2) Enzyme-Linked-Immunosorbent-Assay (ELISA) kit for phospho-ERK and 
phospho-p38 
The ELISA kit were purchased from Assay Designs Inc. and for quantifying the 
phospho-ERK and phospho-p38 in the cell supernatant. Either monoclonal antibody 
to ERK or p38 immobilized are coated on a microtiter plate. The primary antibody is 
a rabbit polyclonal antibody to phospho-ERK or phospho-p38. The conjugate 
antibody is goat anti-rabbit IgG conjugated to horseradish peroxidase. 
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(3) BD Mercury™ TransFactor Kits 
The kit was purchased from BD Biosciences Corp. It is a ELISA-based kit that can 
detect the quantity of NF-KB. Oligonucleotides containing the consensus binding 
sequences for a variety of transcription factors are coated on the plate. The bound 
transcription factors are detected by a specific primary antibody to NF-KB p50. A 
horseradish peroxidase-conjugated secondary antibody is also included in the kit to 
detect the bound primary antibody. 
(4) p38 MAP kinase assay kit 
The kit was purchased from Cell Signaling Technology Inc, MA, USA. It contains 
all reagents required to measure p38 MAP kinase activity including immobilized 
phosphorylated-p3 8 (Thrl80/Thrl82) monoclonal antibody on agarose G, 
phosphorylated-ATF-2 (Thr 71) antibody (rabbit polyclonal IgG), ATF-2 fusion 
protein, kinase buffer, and 1 OmM ATP. 
2.1.11 Reagents and buffers for agarose gel electrophoresis 
(1) Ethidium bromide (EtBr) solution 
The solution (10 mg/ml) was purchased from Gibco Invitrogen Corp and used for 
agarose gel electrophoresis of nucleic acids at 0.5 fj.g/ml. 
(2) Tris-acetate-EDTA (TAE) electrophoresis buffer (lOX) 
TAE buffer (lOX Ultra Pure) from Gibco Invitrogen Corp contained 400 mM 
Tris-acetate and 10 mM EDTA at pH 8.3. It was diluted to IX TAE buffer in agarose 
DNA electrophoresis. • 
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(3) 100 base pair DNA ladder marker 
100 base pair DNA ladder marker (Gibco Invitrogen Corp) was buffered in TE 
Buffer at concentration of 1 \xgl\xl This reagent was 10-fold diluted with loading 
buffer and TE buffer, and 5 ,LI1 of the diluted DNA ladders was used per lane. 
(4) Agarose gel 
Agarose gels (1% and 2%) were prepared by dissolving Ig and 2g agarose (Gibco 
Invitrogen Corp) respectively in 100 ml TAE buffer (0.5X) by heating in microwave. 
The 1% agarose gel was used for RNA gel electrophoresis while the 2% agarose gel 
was used for DNA and PGR products gel electrophoresis. 
2.1.12 Reagents and buffers for SDS-polyacrylamide gel electrophoresis (PAGE) 
(1) 30% (w/v) acrylamide solution 
The 30% acrylamide/Bis solution (29:1) was purchased from Bio-Rad Laboratories, 
CA, USA. It was light-protected and stored at 4°C. 
(2) 10% (w/v) ammonium persulfate (APS) solution 
This was prepared by dissolving 0.5 g APS (Sigma Chemical Co) in 5 ml double 
distilled water. The solution was kept in 500 |LI1 aliquots at -20°C until use. 
(3) Tris-HCl buffer (pH 7.5) 
Tris[hydroxyImethyl] amino methane (Tris) from Sigma Chemical Co was prepared 
as 1 M stock solution in DEPC-treated double distilled water. The buffer was adjusted 
to pH 7.5 with hydrochloric acid (HCl), autoclaved and stored at 4°C. 
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(4) Upper buffer for stacking gel and lower buffer for separating gel 
The upper buffer was a 0.5 M Tris-HCl buffer adjusted to pH 6.8 and the lower 
buffer was a 1.5 M Tris-HCl buffer adjusted to pH 8.8. Both buffers were kept at 4°C. 
(5) 10% sodium dodecyl sulfate (SDS) solution 
This was prepared by dissolving 10 g SDS (Sigma Chemical Co) in 100 ml double 
distilled water and kept at room temperature. 
(6) N,N，N,,N’-Tetm-methylethylenediamine (TEMED) 
TEMED purchased from Sigma Chemical Co, was used to initiate the 
polymerization of SDS-polyacrylamide gel. It was stored at 4°C in dark. 
(7) Tris-Glycine-SDS electrophoresis buffer (lOX) 
Tris-glycine-SDS electrophoresis buffer lOX concentrate containing 0.25 M 
Tris-HCl, pH 7.5, 1.92 M glycine and 1% SDS in double distilled water was filtered 
by a 0.2 |Lim millipore filter and stored at 4°C. This concentrate was diluted fresh to 
IX working buffer solution for SDS-PAGE. 
(8) Laemmli sample buffer 
Laemmli sample buffer from Bio-Rad, contained 62.5 mM Tris-HCl, pH 6.8, 25% 
glycerol, 2% SDS and 0.01% bromophenol blue. Before use, 50 |il of 2-ME was 
added to 950 |il of sample buffer for a final concentration of 5% 2-ME, 710 mM. One 
part of sample was diluted with two parts of sample buffer. 
(9) Prestained SDS-PAGE standards • 
4 4 
Chapter 2 Materials and Methods 
The prestained SDS-PAGE standards (Bio-Rad Laboratories) contained a blue dye 
attached to standard proteins including phosphorylase B (104 kDa), bovine serum 
albumin (81 kDa), ovalbumin (47.7 kDa), carbonic anhydrase (34.6 kDa), soybean 
trypsin inhibitor (28.3 kDa) and lysozyme (19.2 kDa). The standard proteins (total 
625 \ig) were prepared in 33% (v/v) glycerol, 3% SDS, 10 m M Tris (pH 7.0), 10 m M 
DTT, 2 m M EDTA, 0.01% NaNs, and stored at -20°C. 
2.1.13 Reagents and buffers for Western blot analysis 
(1) Antibodies 
Rabbit anti-phospho-ATF-2 (Thr71) and anti-phospho-lKB-a (Ser32) polyclonal 
antibodies were supplied by Cell Signaling Technology Inc. Horseradish peroxidase 
conjugated donkey anti-rabbit Ig secondary antibody was purchased from Amersham 
Pharmacia Biotech, Uppsala, Sweden. 
(2) PVDF Western blotting membranes 
The microporous polyvinylidene difluoride (PVDF) membrane (pore size: 0.45 ]Lim) 
was purchased from Amersham Pharmacia Biotech Ltd, Uppsala, Sweden and was 
stored at room temperature. 
(3) Tris-glycine buffer (lOX) 
Tris-glycine buffer lOX concentrate consisting of 0.25 M Tris-HCl, pH 7.5 and 
1.92 M glycine in double distilled water was filtered by a 0.2 |u.m millipore filter and 
stored at 4°C. 
鶴 
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(4) Tris-glycine-methanol transfer buffer ( I X ) 
The transfer buffer was prepared by mixing 20% methanol in I X Tris-glycine 
buffer, and was kept at 4°C 
(5) Tris-buffered saline tween 20 (TBST) washing buffer 
This consisted of 10 m M Tris-HCl (pH 7.4), 150 m M sodium chloride and 0.05 % 
(w/v) Tween 20 (Sigma Chemical Co). The solution was kept at 4°C. 
(6) 5 % Non-fat mi lk solution (blocking solution) 
Five grams of non-fat milk powder (San Hua Co, Hong Kong) was freshly 
dissolved in 100 ml TBST washing buffer. The solution was used as a blocking 
solution. 
(7) ECL Western blotting analysis system 
It was a Western blotting detection kit purchased from Amersham Pharmacia 
Biotech Ltd. The kit contained a detection reagent 1 (62.5 ml), detection reagent 2 
(62.5 ml), anti-mouse Ig secondary antibody (horseradish peroxidase-linked whole 
antibody from sheep, 100 |LI1), anti-rabbit Ig secondary antibody (horseradish 
peroxidase-linked whole antibody from donkey, 100 |LI1), and 5 g blocking reagent. 
The kit was used for the detection of either mouse or rabbit membrane bound primary 
antibodies and stored at 4°C. 
(8) ECL films (Hyperfilm 丁^  ECL 
The Hyperfilm ™ ECL ^^ was a high pefformance chemiluminescence fi lm used 
for Western blot analysis. It was purchased from Amersham Pharmacia Biotech Ltd. 
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2.1.14 Reagents and buffers for cDNA expression array analysis 
(1) Non-radioactive GEArray™ kits 
GEArray Q-series Human Inflammatory Cytokine/Receptor was purchased from 
SuperArray Bioscience Corp, Bethesda, MD, USA. Each Q-series array membrane 
comprised 96 marker genes in quadraplicate, 4 positive controls including (3-actin, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), cyclophilin A and ribosomal 
protein LI3a, and a negative control, bacterial plasmid pUC18. 
(2) RNasin⑧ ribonuclease inhibitor 
The enzyme from Promega Corp, WI, USA was supplied in 20 m M 
HEPES-potassium hydroxide (pH 7.6), 50 m M potassium chloride, 8 mM 
dithiothreitol (DTT) and 50 % (w/v) glycerol. Its concentration was 40 units/|il, and 
served to inactivate RNase by non-covalent binding. 
(3) Deoxynucleoside triphosphates (dNTPs) 
Also from Promega Corp, the package consisted of separated vials containing 
sodium salt of dATP, dCTP, dGTP, and dTTP at concentration of 100 m M (pH 7.5). It 
was used to freshly prepare the dNTP mix in cDNA labeling. 
(4) Salmon sperm DNA solution 
The solution was purchased from Gibco Invitrogen Corp and kept at -20°C. It was 
prepared from phenol-chloroform extracted salmon sperm DNA with average size of 
龜 
< 2000 bp at concentration of 10 mg/ml in DEPC-treated water. The DNA was used at 
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concentration of 100 |Lig/ml in both the prehybridization and hybridization solutions. 
(5)Biotin-16--dUTP 
This is the tetralithium salt of biotinylated-dUTP at a concentration of 1 mM and 
from Roche Diagnostics Corp, IN, USA. It was used for cDNA labeling and kept at 
-20°C. 
(6) MMLV-reverse transcriptase 
The enzyme from Promega Corp was supplied at a concentration of 200 unit/j^d and 
buffered in 20 m M Tris-HCl (pH 7.5), 200 mM NaCl, 0.1 mM EDTA, I m M DTT, 
0.01% Nonidet⑧ P-40 and 50% glycerol. It was kept at -20°C. 
(7) 20X SSC solution 
20X SSC solution consisted of 3M NaCl and 0.3M sodium citrate at pH 7.0, and 
was purchased from Gibco Invitrogen Corp. It was diluted to 2X and O.IX SSC in 
washing solution for the superarray experiments. 
2.1.15 Reagents and buffers for cell viability and proliferation assay 
(1) Thiazolyl blue tetrazolium bromide (MTT) 
It is purchased from Simga-Aldrich Inc., Missouri, USA. MTT was dissolved in 
PBS to 5mg/ml and stored at -4°C. 
(2) Cell proliferation ELISA, 5-bromo-2'-deoxyiiridine (Brdu) (colorimetric) 
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The kit was purchased from Roche Diagnostics GmbH, Penzerg, Germany. It is a 
colorimetric immunoassay for the quantification of cell proliferation based on the 
measurement of BrdU incorporation during D N A synthesis. It consists of BrdU in 
PBS (lOmM，pH7.4), f ixing and denaturing solution, anti-BrdU monoclonal antibody 
conjugated wi th peroxidase, antibody dilution solution, washing buffer and substrate 
solution. 
2.1.16 Reagent kit for endotoxin level assay 
QCL-1000 ⑧ Chromogenic Limulus Amebocyte Lysate (LAL) Test was purchased 
from Cambrex Bio Science Walkersville Inc, MD, USA. The kit contains the Limulus 
Amebocyte Lysate (LAL) prepared from the circulating amebocytes of the horseshoe 
crab Limulus polyphemiis, E. coli endotoxin and chroniogenic substrate. 
2.2 M e t h o d s 
2.2.1 HMC-1 cell cultures -
HMC-1 cells were maintained in I M D M at a density between 3 and 7 x ICP cells/ml 
supplemented with 10 % (vol/vol) HI FCS (Gibco Invitrogen Corp), and 1.2 m M 
a-thioglycerol (Sigma Chemical Co). They were kept under a humidified atmosphere 
with 5 % CO2 at 37°C and subcultured every 4 days. 
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2.2.2 Flow cytometry of cell surface expression of ICAM-1 and ICAM-3 
HMC-1 cells (5 x 10^ cells/0.5 mi) after preceding treatment were harvested and 
resuspended with cold phosphate buffered saline (PBS) supplemented with 0.5 % 
bovine serum albumin (BSA). After blocking with 2 % human pooled serum for 20 
min at and washed with PBS supplemented with 0.5 % BSA, cells were incubated 
either with FITC-conjugated mouse anti-human ICAM-1 and ICAM-3 monoclonal 
(mAb) antibody or fluorescein-conjugated mouse IgGi and IgG2a isotype for 30 min 
at 4°C in dark. After washing, cells were finally resuspended in 1 % 
paraformaldehyde in I X PBS as fixative. Cell surface expression of ICAM-1 and 
ICAM-3 was then analyzed by flow cytometry (FACSCalibur analyser, Becton 
Dickinson Biosciences Corp, CA, USA) in terms of mean fluorescence intensity 
(MFI). 
2.2.3 Total cellular RNA extraction 
Total RNA from HMC-1 cells (3 x 10^ cells) was extracted using RNeasy Mini Kit 
(Qiagen GmbH). Briefly, HMC-1 cells were lysed and homogenized in the presence 
of a highly denaturing guanidinium isothiocyanate-containing buffer that immediately 
inactivated RNases to ensure isolation of intact RNA. Ethanol was added to provide 
appropriate binding conditions and the sample was then applied to an RNeasy mini 
spin column where the total RNA bound to the membrane and contaminants were 
efficiently washed away. High-quality RNA was then eluted in 40 |LI1 of RNase-free 
water after 15 min on-column DNA digestion. 
翁 
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2.2.4 Reverse Transcription — Polymerase Chain Reaction (RT-PCR) 
Extracted total RNA was reverse transcribed into first-strand complementary DNA 
using First-Strand cDNA Synthesis Kit (Amersham Pharmacia Biotech Ltd) according 
to instruction of manufacturer. PGR was performed in a reaction mixture containing 3 
m M MgCh, 200 |LIM dNTPs, 1 unit of AmpliTaq Gold DNA polymerase (Perkin 
Elmer Corp), 50 pmol of 5' and 3' primers (Gibco Invitrogen Corp) in PGR reaction 
buffer (30 sec at 94°C for denaturing, 30 sec at annealing temperature specific for 
each pair of primers and 45 sec at 72°C for elongation) from 25 to 35 cycles for 
different primers, after an initial 12 min of denaturation at 94°C. A l l RT-PCR were 
performed in the linear range of the PGR reaction according to the preliminary 
experiment. The amount of RNA used was normalized by comparison with the 
amplification of human p-actin mRNA. After the amplification reaction using 
PTC-200 DNA EngineTM (MJ Research, Inc., MA, USA), PGR products were 
electrophoresed on 2 % agarose gel in 1 x TAE buffer (pH 8.0) and stained with 
ethidium bromide. 
2.2.5 Agarose gel electrophoresis 
Both 1% and 2% agarose gels (w/v) were prepared in I X TAE (pH 8.3) containing 
0.5 |ig/ml ethidium bromide. RNA (0.5 -1.0 \.ig) or 5 }iL of PGR product or 1 ^ig of Ik 
base-pair DNA ladder, was mixed with 2 jiL of fast dye loading buffer (5X) 
containing 0.05% (w/v) bromophenol blue, 40% (w/v) sucrose, 0.1 M EDTA (pH 8.0) 
and 0.5% sodium dodecyl sulfate (SDS). Electrophoresis was performed in a 
horizontal electrophoretic tank (Hoeffer, PJjarmacia Biotech) with an agarose gel 
immersed in 1 x TAE by applying the mixture into the sample well under constant 
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voltage of 180V for 20 minutes. The bands were visualized under UV. Images were 
taken from Gene Genius Gel Documentation System (Syngene Inc., Cambridge, UK). 
2.2.6 Quantitative analysis of IL-8, IP-10,MCP-1 and RANTES 
HMC-1 cells (6x 10^ cells/0.3 ml) were treated for 24 h and the concentrations of 
chemokines in culture supernatant were measured by cytometric bead array (CBA) 
(BD Pharmingen Corp) using a FACSCalibur f low cytometer (Becton Dickinson, 
CA, USA). The kits contained five bead populations with distinct fluorescence 
intensities and they have been coated with capture antibodies specific for different 
cytokines and chemokines. The bead populations could be resolved in the FL3 channel 
of f low cytometer. First, 50 j i l plasma or culture supernatants were incubated with 50 
|il different capture beads mixtures and 50 fil PE-conjugated detection antibodies. The 
mixture formed a sandwich complex and after 3 h incubation, the capture beads were 
washed and re-suspended for sample data acquisition using Cell Quest (FACSCalibur). 
The sample results were finally generated in graphical format using the BD CBA 
analysis software. 一 
2.2.7 Quantitative analysis of 1-309 and MIP-1(3 
Culture supernatant was collected after treating the HMC-1 cells (6x 10^ cells/0.3 ml) 
for 24 h. 1-309 and MIP- ip were measured by ELISA for 1-309 and MIP- ip ( R & D 
System Inc). 
2.2.8 Detection of phosphorylated-ERK and phosphorylated-p38 MAPK 
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HMC-1 cells (3 x 10^) after preceding treatment were washed with PBS and lysed 
in 0.15 ml RIPA cell lysis buffer (Assay Designs Inc). The concentrations of 
phosphorylated-ERX and phosphorylated-p38 M A P K in cell lysate of HMC-1 cells 
were quantitated by ELISA using the reagent kits of Assay Designs Inc. 
2.2.9 Detection of NF-KB activity 
Nuclear proteins of HMC-1 cells (1 x 10^) were extracted with N E - P E R ™ nuclear 
and cytoplasmic extraction reagents (Pierce Chemical Co) according to the 
manufacturer instructions. Nuclear extracts were subjected to NF-KB protein/NF-KB 
oligonucleotide binding using Mercury™ TransFactor NF-KB p50 kit (BD 
Biosciences Corp) for the determination of NF-KB activity. 
2.2.10 Detection of phosphorylated-ATF-2 
Total cellular protein from HMC-1 cells (3 x 10^) after preceding treatment were 
lysed in 0.15 ml RIPA cell lysis buffer (Assay Designs Inc). p38 MAP kinase kit (Cell 
Signaling Technology Inc) was used to detect phosphorylated-ATF-2. In brief, the 
monoclonal phospho-specific antibody to p38 MAP kinase (Thrl80/Thrl82) was used 
to selectively immunoprecipitate active p38 MAP kinase from cell lysates. The 
immunoprecipitate was later incubated with ATF-2 fusion protein in the presence of 
ATP and kinase Buffer; this allows immunoprecipitated active p38 MAP kinase to 
• 
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phosphorylate ATF-2. Phosphorylation of ATF-2 was then assessed by Western 
blotting. 
2.2.11 Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) 
A Bio-Rad Min i -PROTEAN apparatus was used for discontinuous polyacrylamide 
gel electrophoresis. The recipe of the stacking gel was 0.187 M Tris.HCl, pH 6.8, 5% 
acrylamide, 0.1% SDS, 0.1% APS, 0.1% TEMED, while the lower separating gel was 
0.375 M Tris.HCl, pH 8.8, 12.5% acrylamide, 0.1% SDS, 0.1% APS, 0:075% 
TEMED. The separating gel solution mixed as the above recipe was casted into the 
vertical gel glass plates of sizes [Inner: 7.3 x 10.2 x 0.1 cm; Outer: 8.3 x 10.2 x 0.1 
cm (h X w X d)]. A layer of 0.1 % SDS was laid on the top to assist the formation of a 
straight line interphase. After the separating gel was set, the 5 % polyacrylamide 
stacking gel was set with a comb to form ten wells of sizes 1.5 x 0.5 x 0.1 cm (h x w 
X d). Electrophoresis was carried out using Tris-Glycine-SDS Running Buffer at a 
constant voltage of 100 for about 100 — 120 min. After electrophoresis, the gel was 
either used for immunoblotting or stained with Coomassie brilliant blue dye (0.2 % R 
250 Coomassie brill iant blue，50 % methanol, 10 % acetic acid) for 1 h and de-stained 
with a solution of 5 % methanol and 10 % acetic acid. 
2.2.12 Western blot analysis 
An equal amount of proteins was subjected to 10% SDS-PAGE before blotting onto 
a PVDF membrane (Amersham and Phafmacia Biotech Corp, NJ, USA). The 
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membrane was blocked with 5 % skimmed milk in Tris-buffered saline with 0.05 % 
Tween 20, pH 7.6 for 1 hr at room temperature, and probed with primary rabbit 
anti-human phosphorylated-lKB-a or phosphorylated-ATF-2 , antibody (Cell 
Signaling Technology Inc) at 4°C overnight. After washing, membranes were 
incubated with secondary donkey anti-rabbit antibody coupled to horseradish 
peroxidase (Amersham and Pharmacia Biotech Corp) for 1 hr at room temperature. 
Antibody-antigen complexes were then detected using ECL chemiluminescent 
detection system according to the manufacturer's instructions (Amersham and 
Pharmacia Biotech Corp). 
2.2.13 MTT assay 
HMC-1 cells (2 x 10' cells/0.2 ml) were inoculated into a 96-well plate. Various 
inhibitors at serial concentrations were added to the cells. After 48-h incubation, 50 |j.g 
MTT (Sigma Chemical Co) was added to each well and incubated for 2 h. Viable cells 
uptook MTT and reduced it into dark blue water-insoluble formazan by mitochondrial 
dehydrogenase which reflected the normal function of mitochondria and cell viability. 
The cells were then lysed with DMSO (200 ul) to yield the colour solution. The 
absorbance at OD550nm was measured to quantify the viable cells. 
2.2.14 Cell proliferation assay 
The cell proliferation rate was assayed with the colorimetric BrdU ELISA (Roche 
Diagnostics Corp). HMC-1 cells (2 x ICP celLs/0.2 ml) were inoculated into a 96-well 
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plate. Various stimulator at serial concentrations were added to the cells for 24 h. 
BrdU was then added and incubated with the cells for 4 h. BrdU was incorporated in 
place of thymidine into the DNA of proliferating cells. By adding the anti-brdU 
conjugated with peroxidase and substrate tetramethy-benzidine, the color developed 
thereby directly correlated to the number of proliferating cells. 
2.2.15 Hot water extraction of TCM 
Powdered extract (5 g) of Dong Chong xia Cao (冬蟲夏草，Cordyceps sinensis), 
Huang qi (黃耆，Radix astragali), Bai Bu (百咅[5, Radix Stemonae), Chuan Bei (Jfl貝， 
Bulbus Fritillariae cirrhosae) and Huang qin (黃夸，Radix Scutellariae) were received 
from Institute of Chinese Medicine, the Chinese University of Hong Kong, Hong 
Kong. Autoclaved deionized water (30 ml) was added to each of them and subjected to 
a water bath of 80°C for 2 h. Supernatant was collected after centrifugation at 5000g 
for 30 min and filtered through 0.2 |im polythersulfone filter. The filtered supernatant 
was lyophilized and afterwards reconstituted to 100 mg/ml with IX PBS. The 
reconstituted TCM was stored in -20°C. 
2.2.16 Endotoxin level assay 
The endotoxin level of the TCM was assayed by the Chromogenic Limulus 
Amebocyte Lysate (LAL) Test. TCM in serial concentrations was added to 96-well 
plate and mixed with the LAL for 10 min at 37°C. The substrate solution was then 
mixed with the LAL-sample and incubated at 37°C for an additional 6 min before 
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Stopping by stop reagent. In this process, Gram-negative bacterial endotoxin catalyzed 
the activation of a proenzyme in the LAL. The activated enzyme then catalyzed the 
splitting of pNA from the colorless substrate Ac-lle-Glu-Ala-Arg-pNA. The yellow 
coloured-pNA could be measured photometrically after the reaction was stopped. 
2.2.17 cDNA expression array analysis 
Non-radioactive GEArray Q-series Human Inflammatory Cytokine/Receptor kits 
(SuperArray Bioscience Corp) were used to analyze the gene expression profiles on 
stimulated cells. Briefly, 3 jiig total RNA was used as template for biotinylated cDNA 
probe synthesis. RNA was reverse-transcribed by gene-specific primers with 
biotin-16-dUTP. Biotinylated cDNA probes were denatured and added to the 
hybridization solution. The GEArray membrane dotted with cDNA fragments of 
different specific genes were pre-hybridized at 60°C for 2 hours and then hybridized 
overnight with the biotinylated cDNA probes. The membranes were then washed and 
blocked with GEA blocking solution, and incubated with alkaline phosphatase 
conjugated streptavidin. The hybridized biotinylated cDNA probes were detected by 
chemiluminescent method using the alkaline phosphatase substrate, CDP-iSVa厂⑧.The 
results were analyzed using Bio-Rad Quantity One '^^ ^ software (Bio-Rad 
Laboratories). The relative expression levels of different genes were estimated by 
comparing its signal intensity with that of internal control p-actin. 
2.2.18 Statistical analysis 
翁 
Data in figures were presented either as histograms plus SD or as mean 士 SD in 
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curves. Differences between groups were assessed by the non-parametric 
Mann-Whitney rank sum test. A probability p < 0.05 was considered significantly 
different. A l l analyses were performed using the Statistical software GraphPad Prism 
(GraphPad Prism for Windows, version 3.00, GraphPad Software, Inc. CA, USA). 
* 
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Chapter 3 
Results 
3.1 The effects of cytokines on the expression of ICAM-l and ICAM-3 on HMC-1 
cells 
3.1.1. SCF, TNF-a and IL-13 up-regulated ICAM-1 but not ICAM-3 expression on 
HMC-1 cells 
To generate a profile of cytokines that may regulate ICAM-1 and ICAM-3 expression, 
the effects of SCF (50 ng/ml), TNF-a (20 ng/ml), IL-13 (20 ng/ml)，IL-18 (20 ng/ml) and 
IL-25 (50 ng/ml) were examined after 48 h incubation with the HMC-1 cells. The optimal 
dose and incubation time of the above cytokines had been determined previously for 
significant effect (data not shown). Compared to controls, a slight increase in ICAM-1 
expression by SCF but a significant up-regulation of ICAM-1 expression by TNF-a and 
IL-13 (Figure 3.3A, p < 0.05) were observed. However, IL-18 and IL-25 showed no 
significant effect on ICAM-1 expression (Figure 3.1 A). As shown in Figure 3.IB, ICAM-3 
showed a much higher basal expression level, but all cytokines were not able to upregulate 
its expression. 
3.1.2. SCF, TNF-a and IL-13 up-regulated the mRNA expression of ICAM-1 
As shown in Figure 3.2, SCF, TNF-a and IL-13 but not IL-18 and IL-25 could 
up-regulate the mRNA expression of ICAM-1 after 24 h incubation. 
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3.1.3 The combined treatment of SCF and TNF-a. and SCF and IL-13 showed synergistic 
and additive effect on ICAM-1 expression respectively 
Figure 3.3 shows that the combined treatment of SCF and TNF-a resulted in a 
synergistic up-regulation of I CAM-1 expression. However, the combined treatment of SCF 
and IL-13 was found to have only an additive effect on ICAM-1 expression. 
3.1.4 Synergistic up-regulation of ICAM-1 expression in combined treatment of SCF and 
TNF-a was dose-dependently enhanced by SCF 
To investigate whether the synergistic effect was dose-dependent on SCF or TNF-a, 
serial concentrations of SCF and TNF-a were used in the combined treatment. As shown in 
Figure 3.4, fixed concentration of SCF (50 ng/ml) with serial concentrations of TNF-a (5 -
70 ng/ml) showed that the synergistic effect could not be dose dependently enhanced by 
TNF-a. On the other hand, the synergistic effect could be further enhanced when the SCF 
concentration increased from 10 ng/ml to 100 ng/ml in combination with fixed TNF-a 
concentration (20 ng/ml). 
翁 
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Fig. 3.1. Effects of SCF, TNF-a, IL-13, IL-18 and IL-25 on ICAM-1 and ICAM-3 
expression on HMC-1 cells. HMC-1 cells (1 x 10^ cells/ml) were incubated for 48 h 
without any cytokines, or with SCF (50 ng/ml), TNF-a (20 ng/ml), IL-13 (20 ng/ml), IL-18 
(20 ng/ml), or IL-25 (50 ng/ml). Staining of HMC-1 cells (A) with mAb IgG! isotype 
control antibody (dotted line) and mAb against ICAM-1 (solid line) and (B) mAb IgGia 
(dotted line) and ICAM-3 (solid line) was determined by f low cytometry. Data are 
presented as histograms of relative cell counts with fluorescence intensity. Each histogram 
represents 5 x 1 0 ^ cells. These are representative figures from 5 independent experiments 
with very similar results. Vertical bar indicates cutoff for peak of ICAM-1 or ICAM-3 
staining with control medium. 
m 
62 
Chapter 3 Results 
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Fig. 3.2. Effects of SCF, TNF-a, IL-13, IL-18 and IL-25 on gene expression of ICAM-1 in 
HMC-1 cells. mRNA expression of (3-actin and ICAM-1 of HMC-1 (1 x 10^  cells/ml) after 
treatment with SCF (50 ng/ml), TNF-a (20 ng/ml), IL-13 (20 ng/ml), IL-18 (20 ng/ml) and 
IL-25 (50 ng/ml) for 24 h were analysed by RT-PCR. Representative results are shown 
from triplicates experiments with essentially identical results. 
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Fig. 3.3. Effects of SCF, TNF-a, IL-13, (SCF + TNF-a) and (SCF + IL-13) on the ICAM-1 
expression on HMC-1 cells. HMC-1 cells (1 x 10^ cells/ml) were incubated for 48 h 
without or with SCF (50 ng/ml), TNF-a (20. ng/ml) and IL-13 (20 ng/ml). Percentage 
increase of ICAM-1 expression was calculated as: [MFI after cytokine treatment - MFI 
without treatment]/MFI without treatment x 100%. Results are presented as mean plus SD 
of 7 independent experiments. Mann-Whitney rank sum test was used to assess the 
difference of % increase between single treatment control groups and combined treatment 
group. < 0.05, 0.01. 
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Fia, 3.4. Effects of various concentrations of SCF and TNF-a on the expression of 
ICAM-1 on HMC-1 cells. HMC-1 cells (1 x 10^ cells/ml) were treated with SCF (10 - 100 
ng/ml) and TNF-a (5 - 70 ng/ml) for 48 h. In the combined treatment, a fixed 
concentration of either SCF (50 ng/ml) or TNF-a (20 ng/ml) was used with a serial 
concentration of TNF-a or SCF. ><0.05 for the combined treatment of SCF (100 ng/ml) 
+ TNF-a (20 ng/ml) compared with the combined treatment of SCF (10 ng/ml) + TNF-a 
(20 ng/ml) assessed by Mann-Whitney rank sum test. No significant difference was found 
between the combined treatments of TNF-a (5 - 70 ng/ml) and SCF (50 ng/ml). Results are 
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3.2 The effects of cytokines on the release of IL-8, IP-10, MCP-1, RANTES, 1-309 and 
MIP-lp from HMC-1 cells 
3.2.1 SCF induced the release of IL-8, MCP-1, RANTES, 1-309 and MIP- lp 
As shown in Figure 3.5, SCF could significantly induce IL-8, MCP-1, RANTES, 1-309 
and MIP- lp at 24 h incubation from HMC-1 cells (all p < 0.05). SCF could also 
up-regulate their mRNA gene expression as shown in Figure 3.6. P-actin was used as 
positive control and remained constant in all treatments. 
3.2.2 TNF-a induced the release of IL-8, IP-10, MCP-1, RANTES and 1-309 
TNF-a could significantly induce IL-8, IP-10, MCP-1, RANTES and 1-309 at 24 h 
incubation from HMC-1 cells (Figure 3.5, all p < 0.05). TNF-a could also up-regulate their 
mRNA gene expression as shown in Figure 3.6. 
3.2.3 SCF and TNF-a did not enhance the proliferation rate of HMC-1 
To ensure that the increased release of chemokines was not due to an increased cell 
number under the effect of SCF and TNF-a, a proliferation assay using BrdU was 
performed. Figure 3.7 shows that the SCF and TNF-a did not significantly increase the 
proliferation rate of HMC-1. 
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Fig. 3.5. Effect of SCF and TNF-a on the release of (A) IL-8, (B) IP-10, (C) MCP-1, (D) 
RANTES, (E) 1-309 and (F) MIP- lp from HMC-1 cells. HMC-1 cells (2 x 10^ cells/ml) 
were cultured with or without SCF (50 ng/ml) or TNF-a (20 ng/ml) for 24 h in a 24-well 
plate. IL-8, IP-10, MCP-1, RANTES, and 1-309 and MIP- ip released into the culture 
supernatant were determined by human chemokine CBA kit using f low cytometry and 
ELISA respectively. Results are expressed as the arithmetic mean plus SD from four 
independent experiments. Mann-Whitney rank sum test was used to assess the difference 
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Fig. 3.6. Effects of SCF and TNF-a on gene expression of IL-8, IP-10, MCP-1, RANTES, 
1-309 and MIP-lp in HMC-1 cells. Total RNA was extracted from HMC-1 cells (1 x 
lOVml) after treated with or without SCF (50 ng/ml) or TNF-a (20 ng/ml) for 12 h, and 
then reverse transcribed and analyzed by PCR. The P-actin housekeeping gene was used 
as the control. 
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Fig. 3.7. Effects of SCF and TNF-a on the proliferation rate of HMC-1. HMC-1 cells (2 x 
10^ cells/ml) were treated without or with SCF (10 - 200 ng/ml) and TNF-a (5 -100 ng/ml) 
for 24 h. The proliferation rate was determined by BrdU ELISA. Percentage of 
proliferation when compared to control was calculated as: absorbance value of treated 
cells/ absorbance value of control cells X 100%. 
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3.3 The effects of SCF and TNF -a on the activation of ERK, p38 MAPK and NK-KB 
Since SCF and TNF showed significant effect on ICAM-1, IL-8, IP-10, MCP-1, 
RANTES, 1-309 and MIP- lp on HMC-1 cells, the activation of ERK, p38 MAPK and 
NK-KB signaling pathways were studied to elucidate the intracellular regulatory 
mechanism. Total cellular protein extracted from HMC-1 cells after cytokine stimulation 
was used for the determination of phosphorylated p38 MAPK and phosphorylated ERK; 
while extracted nuclear protein was used for ELISA of N F - K B protein/NF-KB 
oligonucleotide binding assay. 
3.3.1 SCF activated ERK but not p38 MAPK and NF-KB 
SCF could activate ERK (Figure 3.8) but not p38 MAPK (Figure 3.9) and NF-KB 
(Figure 3.1 OB). The SCF activated ERK pathway peaked at 30 min and declined 
afterwards (Figure 3.8). It was also observed that TNF-a did not cause any 
phosphorylation of the ERK (Figure 3.8). 
3.3.2 TNF-a activated p38 MAPK and NF-KB but not ERK 
In Figure 3.9，it was shown that TNF-a caused activation of p38 MAPK reaching peak 
level at 15 min and declined afterwards. Results of Western blot (Figure 3.1 OA) showed 
that the treatment of TNF-a could induce the degradation of IKB-CX, thereby releasing the 
NF-KB for translocation into nucleus. ELISA of NF-KB protein/NF-KB oligonucleotide 
binding (Figure 3.1 OB) showed that the peak level of nuclear translocated NF-KB protein 
occurred at 7 h after treatment of TNF-a or combined treatment of TNF-a and SCF. 
翁 
Afterwards, level of NF-KB protein binding declined, but was found to be higher in the 
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combined treatment of SCF and TNF-a than that of treatment of TNF-a at 18 h. 
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Fig. 3.8. Effects of SCF, TNF-a and SCF+TNF-a on the activation of ERK of HMC-1 
cells. HMC-1 cells (1 x 10^ cells/ml) were stimulated for 5, 15, 30 and 120 min with SCF 
(50 ng/ml), TNF-a (20 ng/ml) and combined treatment of SCF+TNF-a. Extracted total 
cellular protein (10 ng) from treated and non-treated (control) HMC-1 cells were used for 
the ELISA of phosphorylated-ERK. Results are expressed as mean 士 SD of six 
independent experiments. 
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Fig. 3.9. Effects of SCF, TNF-a and SCF+TNF-a on the activation of p38 MAPK of 
HMC-1 cells. HMC-1 cells (1 x 10^ cells/ml) were stimulated for 5, 15, 30 and 120 min 
with SCF (50 ng/ml), TNF-a (20 ng/ml) and combined treatment of SCF+TNF-a. 
Extracted total cellular protein (10 ng) from treated and non-treated (control) HMC-1 cells 
were used for the ELISA of phosphorylated-p38 MAPK. Results are expressed as mean 士 
SD of six independent experiments. 
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Fig. 3.10. Effects of SCF, TNF -a and SCF+TNF -a on the NF-KB activity o f HMC -1 cells. 
HMC-1 cells (1 X 10^ cells/ml) were treated without or with SCF (50 ng/ml), TNF-a (20 
ng/ml) and combined treatment of SCF+TNF-a. In Figure (A), extracted total cellular 
protein (30 after 2 h treatment was used for the detection of phosphorylated IKB-Q by 
Western blot analysis. Representative blot is shown from triplicate experiments with 
essentially identical results. In Figure (B), extracted nuclear protein (30 jig) after treatment 
for 1, 2, 4, 7, 12 and 18 h was used for the ELISA of NF-KB binding to NF-KB 
oligonucleotide. Results are expressed as mean 士 SD of six independent experiments. 
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3.4 The effect of inhibitors of intracellular signal transduction molecules on the SCF 
and TNF-a-induced release of chemokines 
To elucidate which signaling pathway is responsible for the SCF- and TNF-a-induced 
chemokine release, ERK pathway inhibitor PD98059, p38 MAPK pathway inhibitor 
SB203580 and NF-KB pathway inhibitor B A Y l 17082 were used for investigating their 
suppressive effect on the release of chemokines. 
3.4.1 The optimal dose of PD98059, SB203580 and B A Y l 17082 
The cytotoxicity of different inhibitors for different signaling pathways of HMC-1 cells 
was firstly determined. The dose at which at least 80 % cells were viable was used as the 
optimal dosage of the inhibitor. As shown in Figure 3.11, the optimal dose was found to be 
50, 20 and 70 | iM for PD98059, SB203580 and BAY l 17082 respectively. DMSO (1 
ji l/ml) was used as vehicle for PD98059 and BAY l 17082 and it did not have significant 
cytotoxic effect on HMC-1 cells (Figure 3.11). 
3.4.2 PD98059 suppressed the SCF induced IL-8, MCP-1, RANTES, 1-309 and MIP-1(3 
release from HMC-1 cells. 
As shown in Figure 3.12, PD98059 (50 \jiM) could significantly suppress SCF induced 
release of IL-8, MCP-1, RANTES, 1-309 and MIP- lp from HMC-1 cells (all p < 0.05). 
m 
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3.4.3 SB203580 and BAY 117082 differentially suppressed the TNF-a induced chemokine 
release from HMC-1 cells. 
In Figure 3.13, SB 203580 (20 uM) could significantly suppress TNF-a-induced IL-8, 
IP-10, MCP-1 and 1-309 while BAY 117082 (70 | iM) could suppress IP-10 and RANTES 
release from HMC-1 cells (all p < 0.05). 
m 
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Fig. 3.11. Effects of PD98059, SB203580 and B A Y l 17082 on the viability of HMC-1 cells. 
HMC-1 cells were incubated with (A) PD98059，(B) SB203580, (C) BAY 117082 and (D) 
DMSO for 48 h and the viability was assessed by MTT assay. DMSO was used as vehicle 
for inhibitors PD98059 and B A Y l 17082. Results are expressed as mean 士 SD of triplicate 
experiments. 
78 
一 一 一 —————一——————一————————一—— 一 — 一 — 一 — 一 一 
Chapter 3 Results 
(A) ** 
I (B) 
1 丁 20000] 
3 0 - _ I L - 8 i M C P - 1 
丨丨 
I t i l £ T 
g 1 0 0 0 0 - I 
T _ _ T r-n- ^ 
'^f^Jipl：,：；!^-；'； 1 1 
叫 二 ill ^ T 
O^J—— ：丨 u——L_ ——LJ u——L_ 
no inhibitor PD98059 no inhibitor PD98059 
(C) 20n ： (D) 750] ** 
R A N T E S T 1 - 3 0 9 
_ 一 500- r - H 1 1 
一 T 250- 丁 
丁 
I — I ^n "1— 
" I~^~I I~丨~~I 
0 ~ — — U : o-U——U U 
no inh ib i tor P D 9 8 0 5 9 no inhib i tor P D 9 8 0 5 9 
(E) 
750"! 一 
r ^ r ~ i c o n t r o l 
_ 500- M I P - l p 




no inhibitor PD98059 
m 
79 
Chapter 3 Results 
Fig. 3.12. Effects o f PD98059 on the SCF-induced (A) IL-8, (B) MCP-1, (C) RANTES, (D) 
1309 and (E) M I P - i p in HMC-1 cells. HMC-1 cells (2 x 10^ cells/ml) were treated 
without or wi th PD98059 (50 j iM) for 1 h followed by stimulation with SCF for 24 h. The 
f low cytometry based CBA was used to detect IL-8, MCP-1 and RANTES, and ELISA was 
used to detect 1-309. Mann-Whitney rank sum test was used to assess the difference 
between inhibitor-treated group and the non-inhibitor-treated group. Results are expressed 
as mean plus SD of triplicate experiments.尔p < 0.05, < 0.01 and < 0.005. 
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Fig. 3.13. Effects of SB203580 and BAY 117082 on the TNF-a-induced (A) IL-8, (B) 
IP-10, (C) MCP-1 (D) RANTES and (E) 1-309 in HMC-1 cells. HMC-1 cells (2 x 10^ 
cells/ml) were treated without or with SB203580 (20 iiiM) BAY 117082 (70 i iM) for 1 h 
followed by stimulation with TNF-a for 24 h. The chemokine expression was detected 
using cytometric bead array and ELISA. Mann-Whitney rank sum test was used to assess 
the difference between inhibitor-treated group and the non-inhibitor-treated group. Results 
are expressed as mean plus SD of triplicate experiments. < 0.01 and *** /?< 0.005. 
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3.5 The effect of inhibitors of intracellular signal� transduction molecules on the SCF 
and TNF-a-induced upreulation of ICAM-1 
3.5.1 B A Y l 17082 but not SB203580 suppressed the TNF-a-induced ICAM-1 expression 
As shown in Figure 3.14, BAY l 17082 could significantly suppress the effect of 
TNF-a-induced ICAM-1 expression (p < 0.05). SB203580 and PD98059 showed no effect 
on TNF-a-induced ICAM-1 expression on HMC-1 cells (p > 0.05). 
3.5.2 PD98059 and B A Y l 17082 suppressed the combined treatment of SCF and TNF-a 
induced ICAM-1 expression 
Figure 3.14 shows that both PD98059 and BAY l 17082 could significantly suppress the 
combined effect of SCF and TNF-a induced ICAM-1 expression (p < 0.01 and p < 0.05 
respectively). Combined treatment of PD98059 and BAY 117082 could synergistically 
suppress the ICAM-1 expression induced by the combined treatment of SCF and TNF-a {p 
< 0.005). SB203580 showed no effect on any SCF- or TNF-a-induced ICAM-1 
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Fig. 3.14. Effects of PD98059, BAYl 17082 and SB203580 on the SCF- and 
TNF-a-induced ICAM-1 expression on HMC-1 cells. HMC-1 cells (1 x 10^ cells/ml) were 
treated without or with PD98059 (50 j^iM), BAYl 17082 (70 j iM) and SB203580 (20jiM) 
for 1 h followed by stimulation with SCF, TNF-a and SCF+TNF-a for 48 h. The ICAM-1 
expression was detected by flow cytometry using mAb IgGi isotype control antibody and 
mAb against ICAM-1. Results are expressed as MFI and Mann-Whitney rank sum test v/as 
used to assess the difference between inhibitor-treated group and the non-inhibitor-treated 
group under the same cytokine activation. Results are expressed as mean plus SD of 9 
experiments. ’ < 0.05, < 0.01 and < 0.005. 
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3.6 Effects of inhibitors on TNF-a and SCF-induced ERK, p38 MAPK and N F - K B 
activities in HMC-1 cells. 
To confirm the inhibitory effects of PD98059, SB203580 and B A Y l 17082 on the 
activation of ERK, p38 MAPK and NF-KB pathways in HMC-1 cells, the level of 
phosphorylated ERK, ATF-2 and nuclear NF-KB were determined after the pretreatment of 
inhibitors. 
3.6.1 PD98059 suppressed the SCF-induced activity of ERK 
Since PD98059 suppresses the kinase activity of MEK, that is the upstream kinase of 
ERK, an assay of phosphorylated ERK was performed to confirm the inhibitory effect of 
PD98059. Pretreatment of ERK inhibitor PD98059 could suppress the SCF-induced 
phosphorylation of ERK (Figure 3A5A,p < 0.005). 
3.6.2 SB203580 and B A Y l 17082 suppressed the TNF-a induced p38 MAPK and NF-KB 
activity respectively 
As SB203580 inhibits the kinase activity of p38 MAPK, the phosphorylation of its 
downstream substrate ATF-2 can reflect the inhibitory ability of SB203580. Figure 3.15B 
shows that SB203580 suppressed the TNF-a induced p38 MAPK catalyzed 
phosphorylation of ATF-2 in HMC-1 cells. BAY 117082 inhibits the phosphorylation of 
IKB and could significantly decrease the TNF-a-induced translocation of NF-KB into the 
nucleus (p < 0.001, Figure 3.15C) in HMC-1 cells. 
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3.6.3 PD98059 suppressed the enhanced NF-KB activity after the combined treatment of 
SCF and TNF-a for 18 hours 
To illustrate whether the prolonged activation of NF-KB pathway under the combined 
treatment of SCF and TNF-a could be suppressed by inhibitor of ERK pathway, PD98059 
was added before assaying the nuclear translocated NF-KB. The enhanced NF-KB activity 
upon the combined treatment of SCF and TNF-a for 18 hours could be significantly 
suppressed by PD98059 {p < 0.05, Figure 3.16). No significant effect was found in the 
shorter period (2 and 7 h) o f treatment {p > 0.05). 
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Fig. 3.15. Effects o f inhibitors on TNF-a and SCF-induced phosphorylated ERK, p38 
M A P K and NF-KB activities in HMC-1 cells. HMC-1 cells (1 x lo^ cells/ml) were 
stimulated by SCF (50 ng/ml) or TNF-a (20 ng/ml) for different time wi th or without 1 h 
pretreatment of PD098059 (50 j iM), SB203580 (20 } iM) or B A Y l 17082 (70 ^iM). Total 
cellular proteins were extracted from HMC-1 cells for the measurement of (A) 
phosphorylated ERK using ELISA at 30 min and (B) p38 M A P K activity by the detection 
of phosphorylated ATF-2 using p38 MAP Kinase assay kit at 15 min. In Figure (C) nuclear 
protein was extracted at 7 h for NF-KB protein/NF-KB oligonucleotide binding assay. 
Experiments were performed in four independent replicates with essentially identical 
results, and representative results are shown. * * * < 0.005. 
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Fig. 3.16. Effects of PD98059, SCF and TNF-a on the NF-KB activities in HMC-1 cells. 
HMC-1 cells (1 X 106 cells/ml) were pre-treated with or without PD98059 (50 jiiM) for 1 h 
followed by stimulation with TNF-a and SCF+TNF-a. Nuclear NF-KB protein was 
extracted after the treatment for 2, 7 and 18 h. Mann-Whitney rank sum test was used to 
assess the difference between all the treatment within the same time point. Results are 
expressed as mean plus SD of quadruplicate experiments. * < 0.05. 
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3.7 Effect of TNF-a and SCF on the gene expression profile of inflammatory cytokine 
and receptors of HMC-1 cells. 
To obtain the gene expression profile of 96 genes related with inflammation, a gene 
array o f inflammatory cytokines/ chemokines and receptors was used. Figure 3.17 shows 
the hybridization results using cDNA reverse-transcribed from RNA extracted from cells 
treated without or wi th SCF and TNF-a. 
The 96 genes included in the array can be divided into the fol lowing groups: 
• Cytokines: IL-10, IL-11, IL-12A, IL-12B, IL-13, IL-15, IL-16, IL-17, IL-18, IL-1 A, 
I L - I B , IL-2, IL-20, IL-25, IL-4, IL-5, IL-6, IL-9, TGF-p, TGF-(31, TGF-p2, TGF-p3, LT-a, 
LT-p, TNF-a, IFN-y, LEP, MIR 
- C y t o k i n e receptors: IL- lORa, IL-lORp, I L - l l R a , IL-12R(31, IL-12R(32, IL-13Ral , 
IL-13R, IL-15Ra, IL-17R, IL-18R1, I L - l R l , IL2Ra, IL-2R(3, IL-2R, IL-5a, IL-6R, IL-6ST, 
IL-9R, LT-(3R, TNF-aRl，TNF-aR2 
• Chemokines: 1-309, eotaxin, MCP-4, HCC-1, MIP-15, HCC-4, TARC, PARC, SCYA19, 
MCP-1, MIP-3a, MIP-2, MDC, MPIF-1, MPIF-2, TECK, M lP - l a , SCYA4, RANTES, 
MCP-3, MCP-2, SDF-1, IP-10, I-TAC, SCYB13, ENA-78, GCP-2, lymphotactin, SCM-lp， 
fractalkine, EMAP-2, SDF-2 
• Chemokine receptors: CCR-1, CCR-2，CCR-3, CCR-4, CCR-5, CCR-6, CCR-7, CCR-8, 
CCR-9, CCXCRl , CX3CR1, CXCR4, CXCR5 
The gene list, layout table with gene symbol and position information are given in 
Appendix I while the results of all detectable genes are shown in Table 3.1. The expression 
of P-actin (G14, H I 4 ) remained constant in both the presence and absence of cytokines. 
The intensity o f P-actin was taken as the positive internal control and given an arbitrary 
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unit of 100. As shown in Table 3.1, HMC-1 cells basally expressed a wide spectrum of 
genes of cytokines, chemokines and their receptors; and the expression of all these genes 
could be differentially affected by the treatment of SCF and TNF-a. 
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Fig. 3.17. Effects of SCF and TNF-a on the gene expression profiles of inflammatory 
cytokine and receptor genes. Total RNA was extracted from HMC-1 cells (A) without, and 
(B) with SCF and (C) TNF-a after 12 h, reverse-transcribed and labeled with biotin, and 
gene expressions were detected using the GEArray Q series cDNA expression kit. In (D), 
location of each gene in the array is denoted as symbols correspondingly. The gene located 
at G14 and H14 (P-actin) were the internal control for each treatment. 
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Table 3.1. Effects of SCF and TNF-a on the gene expression profile of cytokines, 
chemokines and their receptor. 
Arbitrary unit of gene expression taking P-actin 
expression as 100 units 
coordinate symbol gene name control SCF TNF-a 
cytokine receptors 
3A ILIORB IL-10 receptor (3 58 85 80 
G3 IL12RB2 IL-12 receptor/3 2 〇 0 12 
A4 IL13RA1 IL-13 receptora 1 45 85 103 
G4 IL17R IL-17 receptor 54 48 60 
5A IL18R1 IL-18 receptor 1 7 22 23 
6B IL2RA IL-2 receptor 109 151 129 
6C IL2RB IL-2 receptor 0 14 20 
G6 IL5RA IL-5 receptor 229 214 209 
G12 TNFRSFIA TNF receptor 1 13 23 19 
G13 TNFRSFIB TNF receptor 2 57 94 88 
chemokine receptors 
CI CCR2 CC chemokine recetor 2 11 38 31 
F1 CCR5 CC chemokine recetor 5 14 47 55 
A2 CCR8 CC chemokjne recetor 8 40 80 44 
B2 CCR9 CC chemokine recetor 9 0 12 13 
D2 CX3CR1 CX3C chemokine recetor 1 135 145 118 
cytokines 
C5 ILIB IL-IP 85 124 160 
C7 IL9 IL-9 79 57 127 
G2 ILIO IL-10 152 166 174 
E4 IL16 IL-16 42 51 54 
A6 IL25 IL-25 42 90 44 
C12 TGFBl TGF-/S 1 83 92 110 
A8 MIF MIF 0 0 20 
chemokines 
B8 SCYAl 1-309 - 224 209 232 
C8 SCYAll eotaxin 125 133 149 
C9 SCYA2 MCP-1 53 84 111 
D9 SCYA20 MIP-3a 13 21 31 
BIO SCYA3 MlP- la 8 22 65 
DIO SCYA5 RANTES 13 45 72 
D8 SCYB13 BLC 58 66 68 
G i l SCYEl EMAP-2 90 91 90 
F9 SCYA22 MDC 0 0 10 
G9 SCYA23 MPIF-1 0 0 10 
C l l SCYB6 GCP-2 0 8 31 
F l l SCYDl fractalkine 0 26 62 
H l l SDFl SDF-1 0 19 17 
p-actin was taken as the internal control for each treatment and as the 100 arbitrary units of gene 
expression. 
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3.8 The effects of TCM on the SCF-induced 1-309 and MCP-1 from HMC-1 cells 
3.8.1 Endotoxin level of Radix astragali, Radix Scutellariae, Radix stemonae, Bulbus 
Fritillariae cirrhosae and Cordyceps sinensis 
Endotoxin is referred to the LPS complex associated with the outer membrane of 
Gram-negative bacteria. Endotoxin can stimulate the biological activities of leukocytes and 
elicit a wide spectrum of nonspecific pathophysiological reactions such as fever, cachexia, 
anorexia, shock and even death in whole body [Lake et al, 2004]. Since TCM is not 
purified or synthetic chemical compound but cultivated plant, endotoxin may be present in 
the TCM extracts and give false positive results on the HMC-1 cells. The LAL test was 
used to determine the endotoxin levels (2.2.16). It was found that the endotoxin levels of 
Radix astragali, Radix Scutellariae, Radix stemonae, Bulbus Fritillariae cirrhosae and 
Cordyceps sinensis were 16.0 土 5.1，28.3 士 0.6, 2.1 士 0.2, 58.4 ±11.6 and 3.8 士 L4 EU/mg 
respectively (Figure 3.18). To make sure the effects of TCM on HMC-1 cells were not due 
to LPS, polymyxin B，an antibiotic that can bind to LPS, was added to the TCM extracts to 
neutralize the effects of LPS. Previously, polymyxin B (5 }ig/ml) had been established to be 
the optimal dose for neutralizing the effects of endotoxin on PBMC without showing any 
cytotoxicity (data not shown). The same dose was adopted in the experiments on HMC-1 
cells. 
3.8.2 The effects of TCM on the proliferation rate of HMC-1 cells 
In Figure 3.19, it was shown that all 5 TCM hot water extracts could suppress the 
proliferation rate of HMC-1 cells in high concentration. The minimal concentrations of 
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Radix astragali, Radix Scutellariae, Radix stemonae, Bulbus Fritillariae cirrhosae and 
Cordyceps sinensis that could significantly suppress the proliferation rate of HMC-1 cells 
were 1, 0.1, 5, 5, 1 mg/ml respectively (all < 0.05). As shown in Figure 3.20, polymyxin 
B did not affect the effects of TCM on the proliferation rate of HMC-1 cells by comparing 
the results of polymyxin B treated- and non-treated-TCM. 
Three concentrations were chosen for each TCM extracts as the doses used in the next 
experiments. The concentrations are 2, 1 and 0.5; 0.5, 0.2 and 0.1; 5, 2, and 1; 2, 1 and 0.5; 
and 2, 1 and 0.5 mg/ml for Radix astragali, Radix Scutellariae, Radix stemonae, Bulbus 
Fritillariae cirrhosae and Cordyceps sinensis respectively. These concentrations gave 80 士 
20% of proliferation rate when compared to control (Figure 3.19). 
3.9.3 The effects of TCM on the SCF-induced release of 1-309 form HMC-1 cells 
At all concentrations being tested, Radix astragali, Radix stemonae, Bulbus Fritillariae 
cirrhosae and Cordyceps sinensis could not significantly suppress the SCF-induced release 
of 1-309 form HMC-1 cells (all p〉0.05, Figure 3.21 A). Only Radix Scutellariae (0.5, 0.2 
and 0.1 mg/ml) could significantly suppress the 1-309 release (all p < 0.05, Figure 3.21 A). 
Polymyxin B did not enhance or suppress the release of 1-309 after treatment of SCF 
(Figure 3.2IB). It also did not alter the TCM effects as the same trend of results were 
obtained in experiments with or without the addition of polymyxin B. 
3.9.4 The effects of TCM on the SCF-induced release of MCP-1 form HMC-1 cells 
Cordyceps sinensis (2 mg/ml) could significantly enhance the SCF-induced release of 
MCP-1 form HMC-1 cells {p < 0.05, Figure 3.22A). On the other hand, Radix Scutellariae 
m 
(0.5, 0.2 and 0.1 mg/ml) could significantly suppress the MCP-1 release (all p < 0.05， 
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Figure 3.22A). Radix astragali, Radix stemonae and Bulbus Fritillariae cirrhosae did not 
show any significantly effect on the release of MCP-1 (all p < 0.05, Figure 3.22A). 
Polymyxin B did not show any significant effect on the chemokine release (Figure 3.22B). 
m 
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Fig. 3.18 Endotoxin level of TCM. The endotoxin levels of Radix astragali, Radix 
Scutellariae, Radix stemonae, Bulbus Fritillariae cirrhosae and Cordyceps sinensis were 
determined by L A L test and expressed as EU/mg. Results are expressed as mean 士 SD of 
triplicate experiments. 
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Fig. 3.19 Effects of TCM on the on the proliferation rate of HMC-1 cells. HMC-1 cells 
( 2 x 1 0 cells/ml) were treated with (A) Radix astragali, (B) Radix Scutellariae, (C) Radix 
stemonae, (D)Bulhiis Fritillariae cirrhosae and (E) Cordyceps sinensis at concentrations of 
10, 5, 2, 1, 0.5, 0.2, 0.1 mg/ml for 24 h. Al l TQM was mixed with polymyxin B (5 |ig/ml). 
The proliferation rate was determined by BrdU ELISA. Percentage of proliferation when 
compared to control was calculated as: absorbance value of treated cells/ absorbance value 
of control cells X 100%. Results are expressed as the mean plus SD from four independent 
experiments. Mann-Whitney rank sum test was used to assess the difference between all 
treatment groups. < 0.05, < 0.01 and < 0.005 when compared with the control. 
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Fig. 3.20 Effects of polymyxin B treated- and non-treated-TCM on the proliferation rate 
of HMC-1 cells. HMC-1 cells (2 x 10^ cells/ml) were treated with Radix astragali, Radix 
Scutellariae, Radix stemonae, Bulbus Fritillariae cirrhosae and Cordyceps sinensis at 
concentrations of 10，5，2, 1, 0.5 mg/ml for 24 h. TCM was mixed with (A) and without (B) 
polymyxin B (5 ug/ml). The proliferation rate was determined by BrdlJ ELISA. Percentage 
of proliferation when compared to control was calculated as: absorbance value of treated 
cells/ absorbance value of control cells X 100%. 
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Fig. 3.21 Effects of T C M on the SCF-induced 1-309 release from HMC-1 cells. HMC-1 
cells (2 X 106 cells/ml) were treated with Radix astragali (2, 1 and 0.5 mg/ml), Radix 
Scutellariae (0.5， 0.2 and 0.1 mg/ml)， Radix Stemonae (5, 2 and Img/ml) Bulbus 
Fritillariae cirrhosae (5, 2 and 1 mg/ml) and Cordyceps sinensis (2, 1 and 0.5 mg/ml) for 1 
h followed by stimulation with SCF for 24 h. TCM was mixed with (A) and without (Bj 
polymyxin B (5 jdg/ml). 1-309 released in culture supernatant was detected using ELISA. 
Mann-Whitney rank sum test was used to assess the difference between (TCM + 
SCF)-treated group and SCF-treated group. Results are expressed as mean plus SD of four 
experiments. < 0.05, < 0.01 and < 0.005. 
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Fig. 3.22 Effects of T C M on the SCF-induced MCP-1 release from HMC-1 cells. 
HMC-1 cells (2 x 10^ cells/ml) were treated with Radix astragali (2, 1 and 0.5 mg/ml), 
Radix Scutellariae (0.5, 0.2 and 0.1 mg/ml), Radix stemonae (5, 2 and 1 mg/ml) Bulbus 
Fritillariae cirrhosae (5, 2 and 1 mg/ml) and Cordyceps sinensis (2, 1 and 0.5 mg/ml) for 1 
h followed by stimulation with SCF for 24 h. In (A), T C M was mixed with (A) and 
without (B) polymyxin B (5 }ag/ml). MCP-1 released in culture supernatant was detected 
using ELISA. Mann-Whitney rank sum test was used to assess the difference between 
(TCM + SCF)-treated group and SCF-treated group. Results are expressed as mean plus 
SD of four experiments. < 0.01 and < 0.005. 
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Chapter 4 
Discussion 
4.1 Involvement of adhesion molecules and chemokines in mast cell-mediated 
immunological events 
Mast cells are strategically located along the microvasculature in tissues in close 
contact wi th the external environment, such as the skin, lung and intestines. The roles of 
mast cells in a range of inflammatory and immunological events have been well 
established [Marone et al, 2005]• For example, mast cells are involved in IgE-mediated 
mechanisms by cross-linking of surface FceRI molecules [Okumura et al, 2005]. They 
also appear to play a key role in defence against bacterial infections [Marshell et al, 
2004; Malaviya et al, 2004], and interact with cells of the adaptive immune system 
[Galli et al, 2005]. A l l these mast cell-mediated immunological events must be 
.accompanied by accumulation of mast cells. Increase in the local density of mast cells 
within inflamed tissue have been described in a number of diseases such as asthma 
[Macfarlane et al, 2000] and rheumatoid arthritis [Ceponis et al, 1998]. The 
accumulation of mast cells in the inflamed area occurs by recruiting mast cell precursors 
from the circulation through intercellular interactions of surface adhesion molecules on 
mast cells. Local maturation of mast cells then takes place and after having stimulated 
by a range of cytokines in the inflamed tissue, mast cells then become pivotal in 
mediating leukocyte recruitment to augment the acute and chronic inflammation, mainly 
through production of chemokines [Selvan et al，1994]. 
The diverse functions demonstrated by mast cells make us start a project to 
investigate their roles in inflammation by elucidating the changed expression of 
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adhesion molecules and chemokines after cytokine stimulations, the intracellular signal 
transduction governing the responses and also the effects brought by the treatment of 
anti-allergic TCM. 
4.2 HMC-1 as the in vitro mast cell model 
In the present study, we adopted a human leukemic mast cell line (HMC-1) 
[Butterfield et al, 1988] as the in vitro mast cell model. It is well accepted to serve as an 
in vitro model to study basic mast cell functions and signal transduction [Kempna et al, 
2004; Fitzgerald et al, 2004]. In fact, HMC-1 is the only well-established growth 
factor-independent human mast cell line and has been widely employed for in vitro 
studies of human mast cell biology (Wedi et al, 1996). Another two human mast cell 
lines, L A D l and LAD2, established from bone marrow aspirates from a patient with 
mast cell sarcoma/leukemia [Kirshenbaum et al, 2003], however, are SCF dependent and 
therefore not suitable for our investigation on cytokine responses. 
On the other hand, there are also murine mast cell line MC/9 and rat basophilic 
leukemia (RBL) mast cell line. Nevertheless, it is known that characteristic of mast cells 
is species specific and thus both of them are not suitable for the mechanistic study of 
human diseases [Venkatesha et al, 2005]. 
Another way to obtain human mast cells is to culture primary cells from umbilical 
cord blood, bone marrow or peripheral blood. However, it is a time consuming and 
expensive process that involves the magnetic cell sorting of CD34+ cells followed by 
culture in the presence of recombinant SCF and IL-6 for at least 15 weeks. In addition, it 
is noticed that mast cells raised from different tissues show varied responses [lida et al, 
2001]. • 
To start our first project on mast cells, we adopted HMC-1 as our in vitro mast cell 
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model to generate homogenous, robust and reproducible results. 
4.3 The effect of cytokines on the ICAM-1 and ICAM-3 expression on HMC-1 
Adhesion molecules and their counterreceptors control the immune and inflammatory 
responses through their specificity and strength of intercellular and matrix interactions 
[Gonlugur et al, 2004]. They direct the leukocytes from the vascular lumen to migrate 
into tissue. ICAM-1 and ICAM-3, transmembrane proteins with extracellular domains 
made up of IgG-like motifs, have been shown to play important role in the recruitment 
of leukocytes to sites of inflammation and in the mast cell-mediated responses. 
ICAM-1 induces allergic responses by mediating mast cell accumulation into 
inflammatory sites [Wedi et al, 1996]. Profound downregulation of ICAM-1 therefore 
leads to the elimination of the immediate-type hypersensitivity and the subsequent 
inhibition of the late phase reaction [Shimada et al, 2003]. The upregulation of ICAM-1 
expression contributes to the accumulation of leukocytes [Valent et al, 1991] and 
facilitates cell-contact-dependent regulation of immune cells in inflamed tissues [Tom et 
al, 1997]. 一 
ICAM-3 is abundantly expressed on mast cells and is suggested to play a key role in 
adhesive cellular interactions during the initial phase of an immune response [Babina et 
al, 2002]. Monoclonal antibodies directed against ICAM-3 are capable of inducing rapid 
HMC-1 cell aggregation and increasing stimulation-dependent release of the 
pro-inflammatory cytokines IL-6 and IL-8 [Babina et al, 1999]. 
In the present study, after the stimulation of SCF, TNF-a, IL-13, IL-18 and IL-25, 
ICAM-3 failed to show an upregulated expression on HMC-1 (Figure 3.IB). However, 
TNF-a and IL-13 could potently increase the c j l l surface expression of ICAM-1, while 
SCF could slightly increase its expression (Figure 3.3). 
1 0 9 
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In general, ICAM-1 on HMC-1 has shown to be more responsive to different 
cytokines and its upregulated expression has been reported after the treatment of IL-4, 
TNF-a and IFN-y [Wedi et al, 1996]. ICAM-3, on the other hand, may play its role in 
adhesive cellular interactions through its abundant expression (as shown in Figure 3.IB) 
but not a fluidic expression under the stimulation of cytokines. As reported by Juan M 
(1999), only the expression of ICAM-1 but not ICAM-3 varied during eosinophil 
activation, although ICAM-3 is highly expressed in resting eosinophils. Besides, Kessel 
JM (2003) also reported that the expression of ICAM-3 is not enhanced by 
proinflammatory cytokines. However, there is another hypothesis suggesting that 
ICAM-3 on eosinophils retains the cells in agglutinations and downregulation of 
ICAM-3 can facilitate the migration through endothelium cells. In fact, ICAM-3 
down-regulation in eosinophils was recently demonstrated in our laboratory after the 
treatment of IL-25. 
We have also demonstrated the change in expression of ICAM-1 started from the 
transcriptional level by showing an increase in mRNA quantity after 12 h treatment of 
SCF, TNF-a and IL-13 [Figure 3.2]. Moreover, the increase in ICAM-1 expression under 
the stimulation of SCF, TNF-a, IL-13 may also reflect a self-regulatory mechanism in 
adhesivness of mast cells. It has been proposed by Wedi et al that mast cells could 
self-amplify their adhesive properties via the increased synthesis of ICAM-1 stimulated 
by TNF-a, IL-4 and IFN-y [Wedi et al, 1996]. In view of our results regarding the effect 
of SCF and IL-13 that are also synthesized by mast cells [Gessner et al, 2005], we may 
conclude that mast cells possess the autocrine function of self-regulating their cell 
surface expression of ICAM-1. 
Besides, this is the first report of an additive effect of SCF and IL-13 and a synergistic 
effect of SCF and TNF-a on the ICAM-1 cell surface expression (Figure 3.3). We also 
found that the synergistic effect was dose-dependent on SCF but not TNF-a (Figure 3.4)， 
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suggesting it was mainly due to the effects of SCF. A l l these results demonstrate 
cytokines in the inflamed tissue can result in an interactive effect on the expression of 
ICAM-1 and provide important information to design therapeutics to antagonize the 
effect of ICAM-1 in inflammatory disorders. As a matter o f fact, ICAM-1 has been 
shown to play a crucial role in mast cell recruitment to the inflamed tissue and 
interaction wi th other inflammatory cells [Inamura et al, 1998]. It has also been targeted 
for treating different inflammatory diseases [Nishibori et al, 2003; Yacyshyn et al, 1999] 
e.g. Crohn's disease and ulcerative colitis [Van Assche et al, 2002], in which mast cell 
hyperplasia and degranulation are observed [He et al, 2004]. Antisense ICAM-1 has 
actually been administered for treating patients with other inflammatory diseases [Nebal 
et al, 2002]. To further understand the molecular meachanism governing the expression 
of ICAM-1, the intracellular signal transduction regulating the effect of SCF and TNF-a 
was investigated and w i l l be discussed in the later part of my project. 
4.4 The effect of cytokines on the release of chemokines in HMC-1 
Chemokines are small, secreted cytokines that are involved in a variety of immune 
and inflammatory responses, acting primarily as chemoattractants and activators of 
specific leukocytes. Chemokines play an essential role in the pathogenesis of mast cells 
by coordinating trafficking of leukocytes [Bisset et al，2005]. In view of this, researchers 
have tried to study the consequent of leukocyte accumulation under the effects of 
anti-inflammatory compounds, e.g. glucocorticoids on the chemokines generated by 
mast cells [Schramm et al, 2004]. To further facilitate the understanding of chemokine 
induction in mast cells, the effects of SCF, TNF-a, IL-13, IL-18 and IL-25 on the release 
of IL-8, MCP-1, IP-10, RANTES, 1-309 and MIP- lp of HMC-1 cells were studied in my 
project. 
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We demonstrated that only SCF and TNF-a could upregulate the release of 
chemokines. SCF could significantly induce IL-8, MCP-1，RANTES, 1-309 and MIP- ip 
while TNF-a could significantly induce IL-8, IP-10, MCP-1, RANTES and 1-309 at 24 h 
incubation from HMC-1 cells (Figure 3.5, all p < 0.05). IL-13, IL-18 and IL-25, 
however, showed no effect of all these chemokines (data not shown). We have also 
demonstrated that the change in protein level of these chemokines coincided with that of 
the transcript level (Figure 3.6), suggesting that the regulation of these chemokines is 
under transcriptional control. We also showed that the SCF and TNF-a did not pose a 
proliferative effect on HMC-1 cells (Figure 3.7), confirming that the increased released 
of chemokines was not due to an increase in cell number after treatments. 
The potent effect of SCF and TNF-a suggests that these two cytokines are among the 
most crucial cytokines in eliciting the functions of mast cells. In fact, SCF critically 
regulates the migration and survival of mast cell precursors, promotes the proliferation 
of both immature and mature mast cells, enhances mast cell maturation and directly 
induces secretion of mast cell mediator [Nakahata et al, 2002]. In the presence of SCF, 
mast cells predominantly produce pro-inflammatory cytokines including IL - ip , IL-6, 
IL-8, IL-16, and IL-18 [Lorentz et al, 2001]. SCF has been proved to be one of the most 
important factors influencing mast cell phenotype and function in both health and 
disease [Galli et al, 1993]. On the other hand, TNF-a is known to be a key inflammatory 
cytokine and therapeutic target for immunotherapeutic intervention in many chronic 
inflammatory disorders including rheumatoid arthritis, Crohn's disease and psoriasis 
[Holtmann et al, 2004]. It also plays a role in the initiation of allergic asthmatic airway 
inflammation and the generation of airway hyper-reactivity [Thomas , 2001]. 
Our results clearly illustrate one more role of SCF and TNF-a in mast cell-mediated 
diseases, i.e. the chemokine inducing property, by showing profound upregulatory 
effects on IL-8, MCP-1, IP-10, RANTES, 1-309 and MIP- lp on HMC-1 cells. 
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On top of the effect brought out by SCF and TNF-a, we have further confirmed that 
mast cells can take multi-roles in immunity through the diverse biological actions -
exhibited by the 6 different chemokines. 
First o f all, these 6 chemokines are not only chemotactic for either Th l cells (for 
cellular immunity) or Th2 cells (for humoral immunity) but both o f them。Since distinct 
T cell subsets express different chemokine receptors, T h l cells are mostly attracted by 
RANTES, M I P - l p and IP-10, and Th2 cells are mostly attracted by 1-309. MCP-1 and 
IL-8 are effective on both subsets [Sebastiani et al, 2002]. This illustrates that mast cells 
can assume different role by attracting Th l or Th2 cells in different physiological 
conditions. 
Apart from recruiting Th cells, these 6 chemokines are also reported to regulate the 
trafficking of varied subpopulations of leukocytes in different immunological events 
after their release from mast cells。 
MIP- l p has been shown to profoundly recruit T cells from the circulation to lymph 
nodes where the primary immune response is initiated [Tedla et al, 1998]. These studies 
also showed that mast cells are the abundant and major source of MIP- ip in the lymph 
nodes during the immune response [Wang et al, 1998]. On the other hand, MIP-1(3 
cannot chemoattract B-cells, eosinophils, basophils and mast cells. 
1-309，which is constitutively overexpressed by mast cells, is shown to markedly 
increased after stimulation via high-affinity FCE： receptor I (FcsRI ) on mast cells 
[Nakajima et al, 2002]. Another study reported 1-309 chemoattracts Th2 cells to trigger 
the allergic inflammation [Gilchrest et al, 2003]. 
MCP-1, which is also constitutively overexpressed in HMC-1, is the crucial 
chemokine in attracting neutrophils. It has been proposed that peritoneal mast cells are 
the major producers of MCP-1 responsible for the delayed neutrophil recruitment during 
acute peritonitis [Wan et al, 2003]. MCP-1 also attracts eosinophils and macrophages in 
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several inflammatory diseases [Shakoory et al, 2004:. 
IP-10 is shown to be greatly induced by IFN-a in mast cells during innate reponse 
against bacterial infection [Mori et al, 2004]. IP-10 appears to specifically target to Th l 
cells and shows no effect on neutrophils [Farber, 1997]。Allergic dermatitis and other 
chronic inflammatory skin diseases have also shown to be mediated by the Th l cells 
recruited by IP-10 with mast cells as one of the major sources [Sebastiani et al, 2002]. 
IL-8 is found to be chemotactic for all known types of migratory immune cells. 
Reports showed that IL-8 can be induced by SCF and phorbol 12-myristate 13-acetate 
(PMA) on mast cells and is related with inflammatory diseases like atopic dermatitis and 
rheumatoid arthritis [K im et al, 2005]. Another major effect brought out by IL-8 is 
neutrophil recruitment and degranulation [Park et al, 1998]. Intranasal administration of 
IL-8 can induce severe granulocytopenia [Van Zee et al, 1992]. 
It is now clear that mast cells can release a multi-faceted spectrum of chemokines and 
therefore play a pathophysiological role in numerous inflammatory diseases by 
coordinating leukocyte trafficking. 
Since different cell types are involved in the production of SCF and TNF-a during 
different inflammatory disorders, the discussion of when and where SCF and TNF-a be 
produced and their co-relationship with specific diseases are certainly out of the study 
scope. More clinical investigations are waiting to be carried out in this area and may 
provide valuable information on understanding the functions of chemokines in mast 
cell-dependent inflammations for therapeutic intervention. 
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4.5 The regulation of ICAM-1, IL-8, IP-10, MCP-1, RANTES, 1-309 and MIP-ip 
through p-38 MAPK, ERK and N F - K B signaling pathways in HMC-1 
Intracellular signal transduction is a highly interactive network composed of various 
types of protein kinases and other messenger cascades [Dong et al, 2002; Wong et al, 
2004]. Its complexity allows the fine control and integration of the signal transduced that 
can elicit the precise and diversified cellular responses upon different extracellular 
stimulations [Pouyssegur et al, 2002]. Since we had demonstrated that SCF and TNF-a 
had the most significant effect on ICAM-1, IL-8, IP-10, MCP-1, RANTES, 1-309 and 
MIP- ip , we then mainly focused on the effect of SCF and TNF-a on the activation of 
p38 MAPK, ERK and NK-KB signaling pathways to elucidate the intracellular 
mechanism in regulating these adhesion molecule and chemokines. 
The three pathways were chosen for investigation as they have been mostly correlated 
with inflammatory diseases by conducting responses for inflammatory cytokines, 
upregulating adhesion molecules or inducing the release of chemokines to recruit 
inflammatory cells. It has been shown that p38 MAPK is upregulated by 
proinflammatory cytokines IL - lp and TNF-a in inflammatory bone disease [Pantouli et 
al, 2005]. Report also revealed that activity of ERK is significantly higher in asthmatic 
mice than controls and administration of ERK inhibitor can dramatically inhibit 
eosinophilia, airway mucus production, and expression of VCAM-1 in lung tissues in 
the asthmatic mice model [Duan et al, 2004]. The release of chemokines IL-8, IP-10 and 
MCP-1 are shown to be upregulated through the activation of NK-KB pathways in 
bronchial epithelial cells co-culturing with eosinophils [Wong et al, 2005]. 
In the present study, SCF activated ERK while TNF-a activated p38 MAPK and 
NF-KB pathways (Figure 3.8 - 3.10). SCF-mediated activation of ERK peaked at 30 min 
and declined afterwards (Figure 3.8). It was also observed that TNF-a did not cause any 
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phosphorylation of the ERK but caused activation of p38 M A P K reaching peak level at 
15 mins and declined afterwards (Figure 3.8 and 3.9). We have also shown that the peak 
level o f nuclear translocated NF-KB protein occurred at 7 hours after treatment of 
T N F - a or combined treatment of TNF -a and SCF. Afterwards, level o f NF-KB protein 
binding declined, but was found to be higher in the combined treatment of SCF and ‘ 
TNF-a than that o f treatment of TNF-a at 18 h (Figure 3.1 OB). — 
To illustrate the direct connection of the SCF- and TNF-a-induced upregulation of -
ICAM - 1 and chemokines to the activation of ERK, p38 M A P K and NF-KB pathways， 
the inhibitors of the corresponding pathways including PD98059, SB203580 and 
BAY 117082 were used. The optimal doses of these inhibitors was found to be 50, 20 and 
70 | iM respectively that could give the highest inhibitory effect without showing 
significant cytotoxicity (Figure 3.11). 
For the suppressive effect on the release of chemokines, we found that PD98059 (50 
\xM) could significantly suppress SCF-induced release of IL-8, MCP-1, RANTES, 1-309 
and M I P - i p from HMC-1 cells (Figure 3.12). On the other hand, SB 203580 (20 | iM) 
could significantly suppress TNF-a-induced IL-8, IP-10, 1-309 and MCP-1 while BAY 
117082 (70 MM) could suppress IP-10 and RANTES release from HMC-1 cells (Figure 
3.13, all p < 0.05). With these results, we can summarize that SCF-induced upregulation 
of IL-8, MCP-1, RANTES, 1-309 and MIP- ip are mediated by ERK pathway. And under 
the treatment of TNF-a, the increased release of IL-8, 1-309 and MCP-1 is signaled 
through the p38 M A P K pathway; RANTES signaled through the NF-KB pathway, and 
IP-10 signaled through both pathways. Table 4.1 gives a summary of the intracellular 
signaling regulating the SCF and TNF-a effects on the chemokines. 
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Table 4.1. Intracellular signaling regulating the SCF and TNF-a effect on the 
chemokines 
Chemokines SCF-induced upregulation TNF-a induced upregulation 
l O ERK pathway p38 M A P K pathway 
MCP-1 ERK pathway p38 M A P K pathway 
IP-10 SCF did not upregulate its release p38 M A P K pathway and 
NF- KB pathway 
RANTES ERK pathway NF- KB pathway 
1-309 ERK pathway p38 M A P K pathway 
M IP - i p ERK pathway TNF-a did not upregulate its 
release 
For the inhibitory effect on the ICAM-1 expression, it was shown that B A Y l 17082 
but not SB203580 could down-regulate TNF-a-induced ICAM-1 expression on HMC-1 
cells (Figure 3.14). It demonstrates that ICAM -1 expression through the NF-KB pathway 
is independent of the TNF-a-activated p38 MAPK. This result also concurs with the 
result in our previous report of the TNF-a-induced ICAM-1 expression on eosinophils 
[IP et al, 2003]. Besides, we also found that PD98059 could suppress the combined 
treatment of SCF and TNF-a induced synergistic effect of ICAM-1 expression (Figure 
3.14) and the SCF-mediated activation of ERK (Figure 3.15A). Morever，the combined 
addition of PD98059 and B A Y l 17082 could potently inhibit the synergistic upregulation 
of ICAM-1. Together with the synergistic effect of SCF and TNF-a on ICAM-1 
upregulation, we may say SCF acts through the ERK pathway, at least in part, to dose 
dependently enhance the TNF-a-induced ICAM-1 expression of HMC-1 cells. 
In fact, Jiang et al (2002 and 2004) demonstrated a temporal control of NF-KB activation 
by ERK in rat vascular smooth muscle cells. ERK is shown to enhance the persistent but 
麵 
not the transient activation of NF-KB [Jiang et al, 2004]. In concurrence with these 
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findings, our results indicated that combined treatment of SCF and TNF-a could prolong 
the activation of NF-KB when treatment time up to 18 hours (Figure 3.1 OB), and 
PD98059 could suppress the enhanced activation (Figure 3.16). On the other hand, there 
is increasing evidence showing that MAPKs is required for NF-KB-dependent gene 
expression [Carter et al, 1999] and cross-talk between discrete intracellular signaling 
pathways [Wong et al, 2004]. As a result, it is quite possible that ERK can crosstalk with 
the NF-KB upon combined treatment of SCF and TNF-a on ICAM-1 expression to elicit 
the synergistic effects. However, further experiments are required to lay more evidences 
on this type of regulatory mechanisms for the discrete response of mast cells. 
The reason of studying the intracellular signal transduction in cytokine-mediated 
responses is due to the anticipation of discovering specific drug that can target a specific 
component, which is specifically co-related with a disease, in one signaling pathway 
[Kowalski et al, 2001]. It is obvious that global inhibition of any signaling pathway may 
result in serious side effect. Despite the fact that p38 MAPK, ERK and NF-KB pathways 
are all known to be greatly involved in inflammatory diseases, they are also involved in 
normal cellular physiology or mounting effective immune responses [Wong et al, 2004]. 
Ways to minimize systemic toxicity are crucial in this aspect of drug intervention. 
Recently, there are encouraging findings in revealing IKK2 and p65 (components of 
NF-KB pathway) are associated with rheumatoid-arthritis synoviocytes and 
inflammatory bowel disease, respectively [L i et al, 2002]. With the increasing 
knowledge of involvement of signaling pathways in diseases, and advance in 
computerized programme to discover new small molecules to antagonize activation of 
different pathways, identifying individual key component for a specific disease wi l l 
eventually be a new horizon in therapeutics. 
In conclusion, the adhesion property and chemokine generation of mast cells are 
under fine and complicated regulation according to different physiological conditions 
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and the interactive effect of cytokines. Our results therefore provide insight for 
cross-talk between different signaling cascades and a better rationale for the design of 
drug therapy for mast cell-mediated diseases. 
4.6 Further characterization of HMC-1 cells using cDNA array 
Regarding the study of mast cell interaction with inflammatory cells, we have 
elucidated the SCF and TNF-a mediated upregulation of ICAM-1, IL-8, MCP-1, IP-10, 
RANTES, 1-309 and MIP- ip . To further explore the interactive roles of mast cells in 
immunity, we have to target new cytokines as stimulators of HMC-1 and also new 
chemokines for investigation. Although there are hundreds of publications reporting the 
expression of cytokines, chemokines and their receptors on mast cells, the information 
available is fragmented or is some pooled results from all types of mast cells including 
the human cell line ones, rat cell line ones and primary cell cultured ones. 
Consequently, we characterized HMC-1 cells by using an array to simultaneously 
profile 96 genes associated with inflammatory responses. Despite the facts that gene 
expression array can only give semi-quantitative results and the gene level may not 
totally reflects the protein level, gene array is the only array can give information for 
both cytokines and receptors within one hybridization. In Table 4.2, the results of all 
detectable gene expression of cytokine and chemokine receptors are listed with their 
corresponding ligands. Since the gene array only gives semi-quantitative results, the 
effects of SCF and TNF-a are denoted as 'Yes' for upregulation and 'No' for no effect. 
We showed that gene expression of receptors IL-lORp, IL-13Ral, IL-17R, IL-18R1, 
IL2Ra, IL-5Ra, TNF-aRl , TNF-aR2 could be detected without the treatment of SCF 
and TNF-a, suggesting that the corresponding ligands may be able to stimulate mast 
翁 
cells, and elicit ranges of immune responses. It also implies that IL-10, IL-17, IL-2 and 
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IL-5 can be served as our new stimulators in our next study. 
The gene expression array also gave enormous information for understanding the 
roles o f mast cells in mediating immune cascade by revealing the potential cytokines 
and chemokines released. The functions of all cytokines and chemokines being 
expressed in gene level with or without stimulation of SCF and TNF-a are summarized 
in the Table 4.3 and 4.4. The diverse functions illustrated by the cytokines and 
chemokines once again confirm the multiple roles of mast cells in immunity. 
It is also observed that HMC-1 expressed the mRNA of a great number o f chemokines, 
especially after the stimulation of SCF and TNF-a. A l l four subfamilies o f chemokines 
including C-C chemokine family (for example, RANTES, MCP-1, M lP- la , 1-309 and 
eotaxin), the C chemokine family (for example, lymphotactin), C-X-C chemokines (for 
example, IP-10, GCP-2 and SDF-1) and the C-X3-C chemokine family (for example, 
fractalkine), that control different leukocyte recruitment and cellular activation, were 
shown to be expressed (Table 4.4). Besides, some of the cytokines such as IL-10, IL-16, 
TGF-p i and I L - i p also show chemotactic effects on other leukocytes (Table 4.3). These 
may reflect the recruitment of leukocytes is essentially one of the important roles of 
mast cells in the inflamed tissues. In fact, mast cells are among the first group of cells 
arriving the inflammatory sites, it is quite possible that mast cells govern the incoming 
inflammatory cells by releasing different spectrum of chemokines or cytokines under 
different stimulations. Within all the chemokines that show mRNA expression in the 
array, only MCP-1, IP-10, RANTES, 1-309 have already been studied (MIP- lp and IL-8 
are not included in the array) and therefore all other chemokines may serve as our new 
targets for investigation. 
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4.7 Investigating the in vitro anti-allergic activities of a newly developed 
Wheeze-relief formula using cytokine-activated HMC-1 cells 
The study of cytokine-activated HMC-1 cells, not only provided biological and 
pharmacological implications in Western medicine, but also helped in developing 
important parameters to investigate the mechanisms of TCM. 
TCM is well known to enhance body immunity without showing serious adverse 
effects. Therefore, it has attracted researchers to demonstrate its use in age-related or 
chronic diseases. A Wheeze-relief formula composing of 5 herbs of TCM has been 
developing by the Institute of Chinese Medicine, the Chinese University of Hong Kong, 
to treat allergic paediatric asthma. Asthma is a chronic and potentially life-threatening 
pulmonary disease. Its symptoms include coughing, wheezing, shortness of breath and 
chest tightness. Severe dyspnea, which is due to spasm of bronchial smooth muscles, 
swelling of the bronchial mucosa, and hypersecretion of the mucus, can be induced upon 
inhalation of or contact with allergens, such as pollens, house dust mites, insects etc. 
Asthma is an old allergic disease and was well documented in ancient books of TCM. 
Asthma is stated as yin (陰）and qi (氣）deficiencies of the Lung and Kidney. Therefore, 
the Wheeze-relief formula is composed of the herbs which are known to enter the Lung 
(入 0市 /經），including Radix astragali, Radix Scutellariae, Radix Stemonae, Bulbus 
Fritillariae cirrhosae and Cordyceps sinensis [Huang et al, 1999]. 
In our laboratory, in vitro investigation was carried out in the past few years to 
elucidate the mechanisms of how this formula works. We have shown that the 
anti-asthmatic effects may be brought out by immunomodulation on eosinophils and 
PBMC. First of all, the Wheeze-Relief formula could downregulate the expression of 
chemokine receptor CCR3 on eosinophils. Since CCR3 receptor is one of most 
important chemokine receptors on eosinophils, the result suggests that the formula can 
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reduce eosinophils recruitment to the lungs by blocking the chemotactic effects of 
eotaxin, RANTES, MCP-2, 3 and 4 [Heath et al, 1997]. Secondly, surface expression of 
CD49d on eosinophils was also reduced after treating with the formula. CD49d has been 
shown to promote superoxide production from eosinophils through binding with 
VCAM-1 on endothelial cells [Nagata et al, 1995]. Besides, we have also shown that the 
eosinophilic cationic protein (ECP) was profoundly inhibited after the drug treatment. 
As superoxide and ECP are the allergic mediators released by eosinophils 
[Joseph-Bowen et al, 2004], the Wheeze-Relief formula may help to inhibit the 
liberation of cytotoxic substance in asthma. Besides, TNF-a, an important mediator 
in asthma [Ming et al, 1987], was also shown to be dovvnregulated in PBMC after the 
treatment. It suggests that the formula can reduce the severity of allergic inflammation 
by suppressing the release of TNF-a. 
Since this previous study had mainly focused on demonstrating the effects of the 
formula in eosinophils and PBMC, mast cells - another effector cell in asthma - was 
used to further elucidate the effects of the formula. HMC-1 had been shown to increase 
its release of chemokines after the treatment of SCF (Figure 3.5). Within these 
chemokines, 1-309 and MCP-1 are capable to recruit the Th2 cells that play key roles in 
bringing out allergic responses [D'Ambrosio et al, 1998 and Rollins, 2001]. Therefore, 
the effects of the 5 TCM extracts on the released of SCF-induced 1-309 and MCP-1 on 
HMC-1 cells were investigated. Besides, extracts of individual herbs in the formula were 
used in the investigation instead of using the mixed herbs for treatments as before. 
The endotoxin levels of the 5 TCM extracts were firstly assayed. It is because 
endotoxin may be present in the cultivated herbs and affect the biological activities of 
leukocytes [Lake et al, 2004]. It was found that each extract of the TCM contained 
certain amount of endotoxin (Figure 3.18). Consequently, polymyxin B, an antibiotic 
that can bind to LPS, was added to the TCM extracts so as to neutralize the effects of 
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LPS and avoid false positive results in our study. 
The effects of the 5 TCM extracts on the proliferation rate of the HMC-1 cells were 
also performed. The aim of doing this experiment was to obtain suitable doses of TCM 
in the later experiments about the release of 1-309 and MCP-1 from HMC-1 cells. The 
proliferation rate could reflect the general biological functions of the cells. Besides, we 
could then figure out whether the varied quantity of chemokines was due to a change in 
cell number or not. Radix Scutellariae had the most potent suppressive effect on the 
proliferation even at relatively low concentrations (Figure 3.19). It conincides with the 
fact that the active ingredient of Radix Scutellariae, baicalin, can have strong cytotoxic 
activity against bacteria including staphylococci, cholea, typhoid, E coli and 
pneumococci etc. More importantly, intravenous administration of 27 mg of baicalin can 
cause a sudden drop in the leukocyte count [Huang et al, 1999]. On the other hand, all 
TCM extracts could suppress the proliferation of HMC-1 when concentration was high 
enough (Figure 3.19). It may be mainly due to some non-specific toxic substances in the 
extracts that can affect the normal function of the cells. 
Three concentrations were chosen for each TCM extracts that could retain 80 士 20% 
of proliferation rate of HMC-1 cells when compared to control. The concentrations are 2， 
1 and 0.5; 0.5, 0.2 and 0.1; 5, 2, and 1; 2, 1 and 0.5; and 2, 1 and 0.5 mg/ml for Radix 
astragali, Radix Scutellariae, Radix stemonae, Bulbus Fritillariae cirrhosae and 
Cordyceps sinensis respectively (Figure 3.19). 
All concentrations of Radix astragali, Radix stemonae, Bulbus Fritillariae cirrhosae 
and Cordyceps sinensis could not suppress the release of SCF-induced 1-309, showing 
that these TCM extracts could not inhibit the recruitment of Th2 cells by 1-309 released 
from SCF-activated mast cells (Figure 3.21). Radix Scutellariae could significantly 
suppress the release of 1-309. However, it was probably a non-specific effect brought out 
by its high toxicity. It might also be the same case on the release of SCF-induced MCP-1 
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as Radix Scutellariae potently suppressed the chemokine release (Figure 3.22). 
Radix astragali, Radix stemonae and Bulbus Fritillariae cirrhosae were also not able 
to downregulate the release of MCP-1 at all concentrations (Figure 3.22). Interestingly, 
Cordyceps sinensis (2 mg/ml) could significantly increase the SCF-induced MCP-1 
(Figure 3.22) although it could significantly suppress the proliferation rate of HMC-1 • 
cells at this concentration (Figure 3.19E). It may be explained by the immuno-enhancing 
property of Cordyceps sinensis. In fact, MCP-1, unlike 1-309，does not mainly recruit 
Th2 cells. It also attracts monocytes, neutrophils and N K cells and is shown to be one of 
the key chemokines in inflammations. Therefore, Cordyceps sinensis (2 mg/ml) might 
activate the HMC-1 cells and enhance the production of MCP-1. 
Together, we have not found a potent and specific downregulation of SCF-induced 
1-309 and MCP-1 by the 5 individual herbs in Wheeze-relief formula. It suggests that the 
5 extracts do not exert their anti-allergic effects through suppressing the release of 1-309 
or MCP-1 from mast cells. The 5 herbs may act on the mast cells in other ways. 
On the other hand, the investigation of this formula wi l l eventually progress to 
doubled blinded, randomized, placebo controlled clinical trials. The Wheeze-relief 
formula w i l l be in a capsule form consisting of powdered extracts of the five herbs. 
Children and adolescents aged 5 to 18 years with chronic asthma diagnosed according to 
criteria proposed by the American Thoracic Society (ATS) (American Thoracic Society, 
1987) w i l l be recruited. EDTA-anticoagulated peripheral blood (PB) wi l l be collected 
for extracting plasma and total RNA of PBMC. Tests for correlating the severity of 
asthma and prescription of drugs wi l l be performed. 
偽 
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4.8 Concluding remarks and future prospective 
From the present study, we have provided important information in deducing 
biological significance of mast cells in inflammation. A better understanding of the 
recruitment of mast cells and also their interaction wi th other inflammatory cells have 
been facilitated after demonstrating the upregulation of chemokine and adhesion 
molecule expression in cytokine-activated HMC-1 cells. The investigation of the 
intracellular signaling pathways also helps in generating pharmacological implications 
on treating mast cell-mediated diseases. 
We have found that ICAM-1, the crucial adhesion molecule in directing mast cells 
migration from vascular lumen to inflamed tissue, could be upregulated by SCF, TNF-a 
and IL-13. We have also suggested that mast cells can self-regulate their cell surface 
expression of ICAM-1 by an autocrine production of cytokines. Besides, an additive 
effect o f SCF and IL-13 and a synergistic effect of SCF and TNF-a on the ICAM-1 cell 
surface expression were also demonstrated. The study of intracellular signal transduction 
then revealed that the SCF- and TNF-a-induced ICAM-1 expression on HMC-1 ceils 
was mediated by E R K and NF-KB pathway, respectively. Cross talking of these two 
pathways was also demonstrated. The results also suggested that the synergistic 
upregulation of ICAM - 1 expression is due to an enhanced activation of NF-KB pathway 
by the SCF-induced activation of ERK. In this part of study, we found that 
ICAM-1-mediated mast cell recruitment and adhesion are under fine and complicated 
regulation according to different physiological conditions and the interactive effect of 
cytokines. Our results have also provided insight for cross-talk between different 
signaling cascades and a better rationale for the design of drug therapy for mast 
cell-mediated diseases. 
On the other hand，we have found that SCF and TNF-a had potent effects in 
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activating mast cells to release the chemokines IL-8, MCP-1, RANTES, IP-10, 1-309 
and M IP - i p . It suggested that SCF and TNF-a are the key cytokines in the inflamed 
tissue to mediate the mast cell responses in inflammation. Besides, the results 
demonstrated the pathophysiological role of mast cells in numerous inflammatory 
diseases by coordinating leukocyte trafficking through the release of multi-faceted 
spectrum of chemokines. The understanding of the functions of chemokines may help to 
generate therapeutic strategies in treating mast cell-mediated diseases. It is because 
chronic deleterious immune response can be reduced by interfering with the 
inflammatory actions of chemokines through small molecular inhibitors or antagonists 
of chemokine receptors or neutralizing antibodies against chemokines or their receptors 
Rossi et al, 2000]. Certainly, the study in intracellular signal transduction regulating the 
chemokine release yet provided more information for therapeutic interventions. We have 
shown that SCF-induced upregulations of IL-8, MCP-1, RANTES, 1-309 and MIP- lp 
were mediated through ERK pathway. The TNF-a-induced iipregulation of IL-8, MCP-1, 
1-309 and IP-10 were mediated by p38 MAPK pathway. Besides, NF-KB pathway was 
responsible for the TNF-a-induced IP-10 and RANTES. In fact, the application of 
intervention of intracellular signal transduction for treating allergic diseases have been 
investigated using animal model and clinical trials [Duan et al, 2005]. 
In future, we can further characterize the functions of mast cells in inflammation by 
using other cytokines as stimulators. As suggested in 4.2, IL-10, IL-17, IL-2 and IL-5 
can be used since the receptors for these cytokines have been shown to be expressed on 
HMC-1 cells. The release of other chemokines such as exotaxin, MIP-3a, MIP- la , B 
lymphocyte chemoattractant (BLC), endothelial-monocyte activating polypeptide 
(EMAP)-2, macrophage derived chemoattractant (MDC), macrophage procoagulant 
inducing factor (MPIF)- l , granulocyte chemotactic peptide (GCP)-2, fractalkine and 
stromal cell-derived factor (SDF)-l after the cytokine stimulation can also be studied as 
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the mRNA of these chemokines is upregulated by the HMC-1 cells (Table 4.4). 
Another way to further study the interaction of mast cells with other inflammatory 
cells is to assay the expression of cell surface molecules on HMC-1 cells that have been 
cultured with other cells. The co-culture system can mimic the in vivo interaction 
between different types of cells in the inflammatory site. It is quite possible that the cells 
wi l l vary their expression of adhesion molecules or receptors after interacting with other 
cells. Preliminary experiments have been performed on the co-culturing of HMC-1 cells 
and bronchial epithelial cells (BEAS-2B).When we measure the expression of surface 
molecules using flow cytometry, we have to firstly gate the two cell populations by 
using an antibody against SCF receptor (c-kit) that is only present on mast cells. Figure 
4.1 shows that the two types of cells could be distinguished by the MFI generated by the 
antibody against SCF receptor. By using another antibody (conjugated with different 
fluorescence) against adhesion molecule or receptor, we can easily study the varied 
expression of any cell surface molecules before and after co-culturing. 
Another part of my study was to investigate the in vitro anti-allergic activities of the 
Wheeze-relief formula. However, its five herbal components, including Cordyceps 
sinensis, Bulbus Fritillariae cirrhosae, Radix Stemonae, Radix astragali and Radix 
Scutellaria could not show a specific downregulation on the release of SCF- induced 
1-309 and MCP-1 from HMC-1 cells. It suggests that the five herbs do not exert their 
anti-allergic effects through suppressing the release of 1-309 or MCP-1 from mast cells. 
In future, primary cultured mast cells derived from bone marrow, peripheral blood or 
cord blood could be employed to study the potential therapeutic effects of the formula. It 
is because primary mast cells express a much higher level of IgE receptors than that of 
HMC-1 cells. They have been used as a model for investigating the IgE-mediated 
release of allergic mediators including histamine, leukotrienes and prostagladins 
[Inamura et al, 1998]. Consequently, the effects of the 5 TCM extracts on the release of 
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allergic mediators under the IgE challenge could be studied, and the mechanisms of how 
the formula works on mast cells could also be more clearly elucidated. 
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Figure 4.1 The dot plots of HMC-1 cells and BEAS-2B cells using mAb against SCF 
receptor. HMC-1 cells alone (B) gave much higher MFI than that of BEAS-2B cells (A). 
In (C), HMC-1 cells and BEAS-2B that have been co-culturing with each other could 
generate two populations of cells showing different level of MFI. 
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23 Hs. 12503 NM C02189 IL15RA inierlejkin 15 :^ec8GlQi\ alpha 一丨L-15Ra 
29 ?ii2127 M90391 111 6 ~ln-8fl8ykin 15 (lymphQcyte chen^oa-tractant ractoi) ~IL-15 
Intsflsukin 17(cyloicxic T-iymphccyte-asscciated serine 
30 Hs.41724 U32659 IL17 esterase 8) ^ IL-17 
一 31 Hs.1297~U5891? |L17R sapiens IL-17 receotc-r mRNA |lL-17R — 
32 Hs.83077 NM C01562 IU8 18 •irUe-feron-gamma-rducmp c^tor) IL-3 
33 H3,15930?"NM C03855 pBRI ^flej<n 1 8 1 ILIBRI 
一 34 Hs.1722 M2S983 ILIA h.jridiKn 1 .b u ！L-1a 
35 HIi2S256 Ml5330 ILiB ~ i ileileuMi 1 beta ~IL-1b 
- 3 6 |HS.821 ~N:M 0GD877 IL1R1 IT.efleukm-- f^ ceotof type 1 IL-1R1 
37 Hs.25333 U74649 lU R2 Inlerleukin-i receolof type li 丨L-1R2 
38 i¥8S67S U25676 IL2 ~ '•ne-idUM-i 2 ~IL-2 
39 Hs.272373 NM D18724 IL20 rretiajM-i ：： IL2Q 
40 1^ 302014 NM ,021803 IL21 Hano sapiens inlerleuko 21 (IL21) IL21 
41 iilQ927 AL36.5373 丨L25 ~ Likely onhclOQ of mouse mierleukin 25 ~IL25 
42 Hs.1724 X01057 IL2RA Inierleukin 2 receptor, a^pha IL-2 Ra 
43 i¥755S6 m mm IL2RB jmerleukln 2 recsptor. beta IL-2 Rb 
！n'eflsukin 2 (eceptcr. gamma (severe combined 
44 Hs.84 _ C00206 IL2RG inimunodeficiency^  “ IL-2 Rr 
45 ?i j3917 Ml 3932 IL4 i-nerleukin 4 _IL-4 
46 Hs.2247 X04688 115 inieflsukin 5 {colciny.s_da;in(3 facicr. eosmcphin IL^  
‘ 4 7 |HS.S8S76 |M75914 |IL5RA llniefleuKh 5 -eceplor alpha ILL-S Ra 
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48 H3.93S^3 IL5 h:etlej<i"i S!.interferon. be:a 2) iL->3 
49 Hs. 1934GO- NM CC0565 IL6R interleukin 5 receplor |L-6 Ra 
iri'erieukin 5 .siqns丨 ir^a广sducer (op13C, cnccsiatin M 
50 Hs.82065 NM 002184 ILGST recepio-) ^ cp i30 
51 H3.S6C |X^"543 IL9 h te f i s iKh 9 lL-9.-p^10 — 
• 52 lfe.1702 InM CC2186 ILGR hterieuKii 9 •-ecsclcf liL-Q Ra 
‘ 5 3 Hs. 19^236 jNM CC023Q LEP Lepl n (j-iLiine opes^y hoiro.cc; iLeptin 
54 H:s.36 |D12614 LTA LymphQ;Qxin-ajpha :TNF SLCSRFAFTILY msnber ^! TNF-b/L:a 
55 HS.89C ！NM 002341 LT3 lyrrohoicxine-Deta 
HCITO sapiens lyniono'cxm Data recepto' ( T N F R 
56 H3.111S L04270 LTBR super'a-mly. member 3(LTBR - LTbR 
Macrconage migration inh..bitOfy factor :+3l‘/cc;svlalov 
5 ' HS.737S3 NM C02415 MIF inhib ting ractcf} 
Small indueib'e cytokre k、(I-30G. hcnclcgcu-s ic mc j s e 
53 H3.72913 .M57502 SCYA1 Tc3，3) I-3C9 
Small induCibte cvlok.ne siibfan^uv A ;Cys~Cv3'i. member 11 
59 Hs.54裕C iNM 002986 SCYA11 leoiaxifti ^ ‘. Eotaxin 
60 HS.113S3 NM C05400 SCYA13 Smali inducible cytok r e sut>farr ly A {Cys-Cys；.. member ！3 MCP-4 
61 Z4927C SCYA14 Smal inducible cytok re suofsir ly A • Cys-CvSL •rieriber U HCC-1 
62 Hs.272均3 NM ：04167 SCYA15 Smali hcbdtoe cytok re suofam ly A (Cys Cys:丨.ember 15 MlP-1 ceita 
63 Hs. 10453 U91746 SCYA16 Smal i-iduCib'e cytokre subfarr iy A (Cys-Cysi. msmber 16 HCC-4 
TARC 
64 Hs.S57^2 NM C02987 SCYA1" Smal inducible cylok.ne subfamily A (Cys-Cvs). menbef 17 iSCYAUi 
Small inducib e cytokine subffiiniy A iCys-Cysj. Tierrber 18. 
65 HS.1653C A3CCC221 SCYAie ptl-norary and sctiva'ion-rspjiated PARC 
66 HS.50CC2 NM C06274 SCYA19 Smali i'lcjucible cytok r e susfatr Jy A (Cys-Cys). member 1 SCYA19 
Srnail inducib e cytok ne A2 {mcnccyte chetro'actic pfcte r MCP-
67 Hs.3C35^9 X14768 SCYA2 1. hamolcqcus meus9 t:SCYA2i 
68 HS.754S3 U77Q35 SCYA2Q Smali inducible cytok re subfamJy A •Cvs-Cvs). mnber 2： MIP-33 
. ‘ MIP-2 
69 Hs.57507 NM C029a9 SCYA21 Smali inducible cytokire subfan^ i^y A (Cys-Cvs).. menber 21 (SCYA21) 
7Q HS.972C3 NM C0290Q SCYA22 Smsli inducible cytok re suofan' y A ^ Cys-CvsV -rienber 22 MDC 
71 Hs.169191 U85"67 SCYA23 Small i-iducib e cytok r e suofam.v A {Cys-Cvsi. irierrber 23 MPIF-1 
72 H3.247B3S NM ：02991 SCYA24 Smal indue:b!e cytok re suofair. :y A -Cys -Cysl -netrber MPlF-2 
73 HS.504C4 NM 005624 SCYA25 Hunan :l-emok.rfe :TECK) TECK 
74 Hs.73ei7 M23452 SCYA5 Small inducible eytok^re A3 (homologous to motse Mic-1a; MlP-^a 
75 Hs.75703 NM CQ2984 SCYA4 Small inducible cytok re A^ {homcloQCus to no t se Mip-lb: M lP -o 
SCYA5 
76 H3.2413S2 NM CC2965 |SCYA.5 Small inducible cytok re A5 iRANTES) (RANTES) 
Homo sapiens mRNA for norocyte cieirrctac'ic pro:ein-3 
77 Hs.251526 X72308 SCYA7 (MCP-3:' : MCP-3 
Smal inducible cytokine subfarn y A (Cys-Cys), member 8 
70 |HS.271337 |YI0302 ISCYAS lirnonocytechemotactcpfctein 2) IMCP-2 
痛 
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I Ganiira-!n!6'teron incucib-e ear y rsspor.se gene (small 
79 IHS.22幼 NM 001565 SCYB1C ifiducisle cvlOKine subfamiiv B fCvs-X-Cvsi P'OilPIG) 
Small inducibe cvtokre subfairi.y B iCys-X-Cys). rrembsr I-TAG :IP9i 
SO Hs. 103982 Y15220 SCYB11 r (SCY311i 
Small inducib'e cytokre B ^Jbfandy (Cys-X-Cys 'nchfi, 
31 Hs. 100431 NM 006419 SCYB13 membsr 13 (B-celi chsmoai-fSC'anQ SCYB13 
Small inducible cytokine subfamily B (Cys-X-Cysi. inembsr 5 
32 Hs.897乂 NM 002994 SCYB5 (epiheial-derived neuifoohil-3Cbva:i-iq ENA-78 
35 Hs. 16C21 NM CC2993 SCYB6 Huiran chemok're abha 3 iCKA-3: -riRNA GCP-2 
Small inducible cv tok re subfamiiv C. -iiember 1 
54 Hs.3195 023772 SCYC- (ivmohotactn) ‘ ^ lymorio'aclin 
一 35 Hs.1745rD63789 —SCYC2 Sfiiali inducibla cylokine siPfamyv C. -nei-iber 2 SCYC2 
Smal i-iducib'e cytokre subfamily D (Cys-XS-Cys), member 
86 iHs.8D^2G U91B35 SCYD1 1 (fractalkine. neurQ.actini Ffactakine 
StTial! inducible cylck^ re suofarr ly E. nemet 1 fendolhslial 
37 Hs.3335^3 NM 004757 SCYE1 丨r:onocy丨e-adva丨丨ng: SCYE1 
— 0 8 IHS.237356 U16752 SDF1 S-romakeli-derved factor 1 SDF1 
89 H s . 1 i e ~ D 5 Q 6 4 5 SDF2 too sapiens mRNA for SDF2 SDF2 
‘ 9 0 HS.170CQ9 NM .CG3235 TGFA — Trars'O-nina growfi faclor. alpha "~TGF-a 
91 H3.1103 XG2012 TGFB1 Trars-on-imq grov/rn factor, beta ‘ TCFb1 
92 ""fejis3QG M^9154 TGFB2 Transfo-ninq crowth factor, beta 2 TGF b2 
一 93 H 3.2Q25~ NM >03239 TGFB3 Transfp-ming growth facicr. beta 3 ITGF b3 一 
94 HS.24157G XC1394 TNF Tuiror recros s faclor (TNF SLcerfamily msaiber 2l TiNFa 
“ I iTNFRSFt 
95 H3.159 M33294 A Tunof necrosesfac.c;receptor superfami'y member 1A TNFR' 
TNFRSR TNFR2 
96 Hs.25c27a NM 001066 B Htiran turner necrosis c^lor fecepto- 2 :TNFSF1B; 
97 N/A 一 L08752 PUC18 PUG18Plasm^d PNA pUC1S 一 
— 9 8 N/A LQ6752 —PUC13 PUC18 P丨asm:;c DNA pUC18 
“ 9 9 N/A LQ8752 一 PUC13 PUC18 PiasrrjC PNA pUC18 
1GQ Biar-ik Blank Blank Bark 一 0 
101 Blank Blank Blank B 丨3「k 0 
102 Blank Blank Blank B^ark "“ 0 
-103 H$.169^ M33197 GAPD Glycerald8nyde-3-pnosona!s dehycrocerase GAPDH 
104 IHS. 169475" M33197 ~~GAPD Glyceraldenvde-S-onosonaie ciehvcrocerase GAPDH 
Homo sapiens pe[;t dy pio'y! borre'ass A (cycloon lin A) 
105 Hs. 182337 NM-Q2113Q PP!A iPPlA} ‘ cydooninA 
Homo sapiens peptidy^piolyl ssorre-ase A (cydoondin A) 
10S Hs. 182937 N?v]-02113a PPiA (PPiAl ^ cycloonlhA 
Hoiro sapiens peptldy^prolyl jsoms'ase A (cydoo_.i A) 
107 Hs. 182937 NM-021130 PPIA (PPiA； cycloonin A 
Hoiro sapiens peptidy?pro!yl mre-ase A (cydoonlin A) 
108 HS.1B2937 N? -^021130 PP^ A (PPiA) cyclooniinA 
109 i i " l1Sl22 NM 012423 RPL1R iboscna l proisin L^3a (23 Kca h chly bas£ prote r) R?L13A 
110 19122 NM G12423 RPL13~ Rifcoscnal m e h 3a .23 Kca h chly bas:.e prole.n) R?L13A 
“ 1 1 1 Hs.2B8C6rxCC355 _ A C T B Beta Actr: b-aciin 
“ 1 1 2 |HS 288C65 |XG0355 IACTB be.a Act.r |b-actin — 
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